0001582982 false --12-31 Q1 5 P5Y 1 0001582982 2022-01-01 2022-03-31 0001582982 MTBC:CommonStockParValue0.001PerShareMember 2022-01-01 2022-03-31 0001582982 MTBC:Sec11SeriesCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2022-01-01 2022-03-31 0001582982 MTBC:Sec8.75SeriesBCumulativeRedeemablePerpetualPreferredStockParValue0.001PerShareMember 2022-01-01 2022-03-31 0001582982 2022-05-02 0001582982 2022-03-31 0001582982 2021-12-31 0001582982 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001582982 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2022-03-31 0001582982 2021-01-01 2021-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001582982 us-gaap:CommonStockMember 2021-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001582982 us-gaap:RetainedEarningsMember 2021-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001582982 us-gaap:TreasuryStockMember 2021-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2020-12-31 0001582982 us-gaap:CommonStockMember 2020-12-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001582982 us-gaap:RetainedEarningsMember 2020-12-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001582982 us-gaap:TreasuryStockMember 2020-12-31 0001582982 2020-12-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001582982 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001582982 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001582982 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001582982 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001582982 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2022-03-31 0001582982 us-gaap:CommonStockMember 2022-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001582982 us-gaap:RetainedEarningsMember 2022-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001582982 us-gaap:TreasuryStockMember 2022-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001582982 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2021-03-31 0001582982 us-gaap:CommonStockMember 2021-03-31 0001582982 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001582982 us-gaap:RetainedEarningsMember 2021-03-31 0001582982 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001582982 us-gaap:TreasuryStockMember 2021-03-31 0001582982 2021-03-31 0001582982 MTBC:MTBCPrivateLimitedMember 2004-12-31 0001582982 MTBC:MTBCPrivateLimitedMember MTBC:FounderAndExecutiveChairmanMember 2004-12-31 0001582982 MTBC:AssetAndStockPurchaseAgreementMember MTBC:MedMaticaMember 2021-05-31 2021-06-01 0001582982 MTBC:AssetAndStockPurchaseAgreementMember MTBC:MedMaticaMember 2021-06-01 0001582982 MTBC:MedSRMember 2021-06-01 0001582982 MTBC:MedSRMember 2022-03-31 0001582982 MTBC:MedSRMember 2021-12-31 0001582982 MTBC:MedSRMember 2021-05-31 2021-06-01 0001582982 MTBC:MedSRMember 2021-07-01 2021-09-30 0001582982 MTBC:MedSRMember 2021-09-30 0001582982 MTBC:MedSRMember 2022-01-01 2022-03-31 0001582982 MTBC:MedSRMember 2021-01-01 2021-03-31 0001582982 MTBC:Acqisition2021Member MTBC:MeridianBillingManagementCoMember 2022-01-01 2022-03-31 0001582982 MTBC:MedSRPurchasePriceMember 2021-06-01 0001582982 2021-01-01 2021-12-31 0001582982 MTBC:ContractsAndRelationshipsAcquiredMember 2022-03-31 0001582982 MTBC:ContractsAndRelationshipsAcquiredMember 2021-12-31 0001582982 MTBC:CapitalizedSoftwareMember 2022-03-31 0001582982 MTBC:CapitalizedSoftwareMember 2021-12-31 0001582982 us-gaap:NoncompeteAgreementsMember 2022-03-31 0001582982 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2022-03-31 0001582982 us-gaap:OtherIntangibleAssetsMember 2021-12-31 0001582982 MTBC:SVBCreditFacilityMember 2017-10-31 0001582982 MTBC:SVBCreditFacilityMember srt:MinimumMember 2018-09-30 0001582982 MTBC:SVBCreditFacilityMember srt:MaximumMember 2018-09-30 0001582982 MTBC:SVBCreditFacilityMember 2021-09-30 0001582982 MTBC:SVBCreditFacilityMember 2022-03-31 0001582982 MTBC:SVBCreditFacilityMember us-gaap:PrimeRateMember 2017-10-31 0001582982 MTBC:SVBCreditFacilityMember srt:MinimumMember 2017-10-31 0001582982 MTBC:SVBCreditFacilityMember 2017-10-01 2017-10-31 0001582982 MTBC:SVBDebtAgreementMember 2017-10-01 2017-10-31 0001582982 MTBC:SVBDebtAgreementMember 2017-10-31 0001582982 MTBC:SVBCreditFacilityMember srt:MaximumMember 2017-10-31 0001582982 MTBC:SVBDebtAgreementMember MTBC:AdditionalWarrantMember 2017-10-31 0001582982 MTBC:VehicleFinancingNotesMember 2022-01-01 2022-03-31 0001582982 MTBC:InsuranceFinancingMember 2022-03-31 0001582982 2020-03-24 2020-03-25 0001582982 srt:MinimumMember 2020-06-10 2020-06-12 0001582982 srt:MaximumMember 2020-06-10 2020-06-12 0001582982 2020-07-22 2020-07-24 0001582982 MTBC:CivilInvestigationMember 2022-01-01 2022-03-31 0001582982 MTBC:CivilInvestigationMember 2022-03-31 0001582982 MTBC:PhysicianMember 2022-01-01 2022-03-31 0001582982 MTBC:PhysicianMember 2021-01-01 2021-03-31 0001582982 MTBC:PhysicianMember 2022-03-31 0001582982 MTBC:PhysicianMember 2021-12-31 0001582982 MTBC:NonexclusiveAircraftDryLeaseAgreementMember MTBC:KashmirAirIncMember 2022-01-01 2022-03-31 0001582982 MTBC:ExecutiveChairmanMember 2022-01-01 2022-03-31 0001582982 MTBC:ExecutiveChairmanMember 2021-01-01 2021-03-31 0001582982 MTBC:ExecutiveChairmanMember 2022-03-31 0001582982 MTBC:ExecutiveChairmanMember 2021-12-31 0001582982 MTBC:RelatedPartyLeaseMember 2022-03-31 0001582982 MTBC:RelatedPartyLeaseMember 2021-12-31 0001582982 us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:SeriesAPreferredStockMember 2022-03-17 2022-03-18 0001582982 us-gaap:SeriesAPreferredStockMember 2022-03-18 0001582982 us-gaap:SeriesBPreferredStockMember MTBC:FebruaryFifteenTwoThousandTwentyFourAndPriorToFebruaryFifteenTwoThousandTwentyFiveMember 2022-03-31 0001582982 us-gaap:SeriesBPreferredStockMember MTBC:FebruaryFifteenTwoThousandTwentyFiveAndPriorToFebruaryFifteenTwoThousandTwentySixMember 2022-03-31 0001582982 us-gaap:SeriesBPreferredStockMember MTBC:FebruaryFifteenTwoThousandTwentySixAndPriorToFebruaryFifteenTwoThousandTwentySevenMember 2022-03-31 0001582982 us-gaap:SeriesBPreferredStockMember MTBC:OnOrAfterFebruaryFifteenTwoThousandTwentySevenMember 2022-03-31 0001582982 MTBC:AtTheMarketMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001582982 MTBC:AtTheMarketMember 2022-01-01 2022-03-31 0001582982 MTBC:CommonStockWarrantsMember 2021-03-31 0001582982 MTBC:CommonStockWarrantsMember 2021-01-01 2021-03-31 0001582982 MTBC:HealthcareITMember MTBC:TechnologyEnabledBusinessSolutionsMember 2022-01-01 2022-03-31 0001582982 MTBC:HealthcareITMember MTBC:TechnologyEnabledBusinessSolutionsMember 2021-01-01 2021-03-31 0001582982 MTBC:HealthcareITMember MTBC:ProfessionalServicesMember 2022-01-01 2022-03-31 0001582982 MTBC:HealthcareITMember MTBC:ProfessionalServicesMember 2021-01-01 2021-03-31 0001582982 MTBC:HealthcareITMember MTBC:PrintingAndMailingServicesMember 2022-01-01 2022-03-31 0001582982 MTBC:HealthcareITMember MTBC:PrintingAndMailingServicesMember 2021-01-01 2021-03-31 0001582982 MTBC:HealthcareITMember MTBC:GroupPurchasingServicesMember 2022-01-01 2022-03-31 0001582982 MTBC:HealthcareITMember MTBC:GroupPurchasingServicesMember 2021-01-01 2021-03-31 0001582982 MTBC:PracticeManagementMember MTBC:PracticeManagementServicesMember 2022-01-01 2022-03-31 0001582982 MTBC:PracticeManagementMember MTBC:PracticeManagementServicesMember 2021-01-01 2021-03-31 0001582982 MTBC:RevenueCycleManagementandOrionAcquisitionMember 2022-03-31 0001582982 MTBC:OrionAcquisitionMember 2022-01-01 2022-03-31 0001582982 MTBC:OrionAcquisitionMember 2022-03-31 0001582982 us-gaap:AccountsReceivableMember 2021-12-31 0001582982 MTBC:ContractAssetMember 2021-12-31 0001582982 us-gaap:ShortTermContractWithCustomerMember 2021-12-31 0001582982 us-gaap:LongTermContractWithCustomerMember 2021-12-31 0001582982 us-gaap:AccountsReceivableMember 2022-01-01 2022-03-31 0001582982 MTBC:ContractAssetMember 2022-01-01 2022-03-31 0001582982 us-gaap:ShortTermContractWithCustomerMember 2022-01-01 2022-03-31 0001582982 us-gaap:LongTermContractWithCustomerMember 2022-01-01 2022-03-31 0001582982 us-gaap:AccountsReceivableMember 2022-03-31 0001582982 MTBC:ContractAssetMember 2022-03-31 0001582982 us-gaap:ShortTermContractWithCustomerMember 2022-03-31 0001582982 us-gaap:LongTermContractWithCustomerMember 2022-03-31 0001582982 us-gaap:AccountsReceivableMember 2020-12-31 0001582982 MTBC:ContractAssetMember 2020-12-31 0001582982 us-gaap:ShortTermContractWithCustomerMember 2020-12-31 0001582982 us-gaap:LongTermContractWithCustomerMember 2020-12-31 0001582982 us-gaap:AccountsReceivableMember 2021-01-01 2021-03-31 0001582982 MTBC:ContractAssetMember 2021-01-01 2021-03-31 0001582982 us-gaap:ShortTermContractWithCustomerMember 2021-01-01 2021-03-31 0001582982 us-gaap:LongTermContractWithCustomerMember 2021-01-01 2021-03-31 0001582982 us-gaap:AccountsReceivableMember 2021-03-31 0001582982 MTBC:ContractAssetMember 2021-03-31 0001582982 us-gaap:ShortTermContractWithCustomerMember 2021-03-31 0001582982 us-gaap:LongTermContractWithCustomerMember 2021-03-31 0001582982 MTBC:TwoThousandFourteenEquityIncentivePlanMember MTBC:EmployeesOfficersDirectorsAndConsultantsMember 2014-04-30 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2017-12-31 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2017-12-31 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2018-12-31 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2020-05-31 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2020-05-31 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:CommonStockMember 2022-03-31 0001582982 MTBC:AmendedAndRestatedEquityIncentivePlanMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2021-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2022-01-01 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2022-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2020-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2020-12-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2021-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0001582982 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SeriesBPreferredStockMember 2021-03-31 0001582982 MTBC:DirectOperatingCostsMember 2022-01-01 2022-03-31 0001582982 MTBC:DirectOperatingCostsMember 2021-01-01 2021-03-31 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001582982 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001582982 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001582982 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001582982 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001582982 srt:MaximumMember 2020-03-26 2020-03-27 0001582982 srt:MinimumMember 2020-03-26 2020-03-27 0001582982 2020-03-26 2020-03-27 0001582982 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001582982 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-03-31 0001582982 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-03-31 0001582982 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001582982 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001582982 MTBC:HealthcareITMember 2022-01-01 2022-03-31 0001582982 MTBC:MedicalPracticeManagementMember 2022-01-01 2022-03-31 0001582982 MTBC:UnallocatedCorporateExpensesMember 2022-01-01 2022-03-31 0001582982 MTBC:HealthcareITMember 2021-01-01 2021-03-31 0001582982 MTBC:MedicalPracticeManagementMember 2021-01-01 2021-03-31 0001582982 MTBC:UnallocatedCorporateExpensesMember 2021-01-01 2021-03-31 0001582982 us-gaap:SubsequentEventMember MTBC:AzadJammuandKashmirMember MTBC:MTBCBaghPrivateLimitedMember 2022-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure MTBC:Segment

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

**(Mark one)**

|  |  |
| --- | --- |
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

**For the quarterly period ended March 31, 2022**

**or**

|  |  |
| --- | --- |
| **☐** | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

**For the transition period from to**

**Commission File Number 001-36529**

**CareCloud, Inc.**

*(Exact name of registrant as specified in its charter)*

|  |  |  |
| --- | --- | --- |
| **Delaware** |  | **22-3832302** |
| *(State or other jurisdiction of*  *incorporation or organization)* |  | *(I.R.S. Employer*  *Identification Number)* |

|  |  |  |
| --- | --- | --- |
| **7 Clyde Road**  **Somerset, New Jersey** |  | **08873** |
| *(Address of principal executive offices)* |  | *(Zip Code)* |

**(732) 873-5133**

*(Registrant’s telephone number, including area code)*

Securities registered pursuant to Section 12(b) of the Act:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |  | MTBC |  | Nasdaq Global Market |
| 11% Series A Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share |  | MTBCP |  | Nasdaq Global Market |
| 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock, par value $0.001 per share |  | MTBCO |  | Nasdaq Global Market |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |  |
| --- | --- | --- |
| Large accelerated filer **☐** |  | Accelerated filer **☒** |
| Non-accelerated filer **☐** |  | Smaller reporting company **☒** |
|  |  | Emerging growth company **☐** |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. **☐**

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes **☐** No **☒**

At May 2, 2022, the registrant had 15,066,103 shares of common stock, par value $0.001 per share, outstanding.

|  |
| --- |
|  |

**INDEX**

|  |  |  |
| --- | --- | --- |
|  |  | Page |
| [Forward-Looking Statements](#ed_001) | | 2 |
|  |  |  |
| [**PART I. FINANCIAL INFORMATION**](#ed_002) | |  |
|  |  |  |
| Item 1. | [Consolidated Financial Statements (Unaudited)](#ed_003) |  |
|  | [Consolidated Balance Sheets at March 31, 2022 and December 31, 2021](#ed_004) | 3 |
|  | [Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021](#ed_005) | 4 |
|  | [Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2022 and 2021](#ed_006) | 5 |
|  | [Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2022 and 2021](#ed_007) | 6 |
|  | [Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021](#ed_008) | 7 |
|  | [Notes to Consolidated Financial Statements](#ed_009) | 8 |
| Item 2. | [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#sur_001) | 25 |
| Item 3. | [Quantitative and Qualitative Disclosures about Market Risk](#sur_002) | 36 |
| Item 4. | [Controls and Procedures](#sur_003) | 36 |
|  |  |  |
| [**PART II. OTHER INFORMATION**](#sur_004) | |  |
|  |  |  |
| Item 1. | [Legal Proceedings](#sur_005) | 38 |
| Item 1A. | [Risk Factors](#sur_006) | 38 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#sur_007) | 38 |
| Item 3. | [Defaults Upon Senior Securities](#sur_008) | 38 |
| Item 4. | [Mine Safety Disclosures](#sur_009) | 38 |
| Item 5. | [Other Information](#sur_010) | 38 |
| Item 6. | [Exhibits](#sur_011) | 39 |
| [Signatures](#sur_012) | | 40 |

|  |
| --- |
| 1 |

**Forward-Looking Statements**

*Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q are forward-looking statements. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “should,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Our operations involve risks and uncertainties, many of which are outside of our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.*

*Forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties, and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward-looking statements as set forth under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 14, 2022. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to:*

|  |  |  |
| --- | --- | --- |
|  | ● | our ability to manage our growth, including acquiring, partnering with, and effectively integrating acquired businesses into our infrastructure and avoiding legal exposure and liabilities associated with acquired companies and assets; |
|  |  |  |
|  | ● | our ability to retain our clients and revenue levels, including effectively migrating new clients and maintaining or growing the revenue levels of our new and existing clients; |
|  |  |  |
|  | ● | our ability to maintain operations in our offshore offices in a manner that continues to enable us to offer competitively priced products and services; |
|  |  |  |
|  | ● | our ability to keep pace with a rapidly changing healthcare industry; |
|  |  |  |
|  | ● | our ability to consistently achieve and maintain compliance with a myriad of federal, state, foreign, local, payor and industry requirements, regulations, rules, laws and contracts; |
|  |  |  |
|  | ● | our ability to maintain and protect the privacy of confidential and protected Company, client and patient information; |
|  |  |  |
|  | ● | our ability to develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards and third-party software platforms and technologies, and protect and enforce all of these and other intellectual property rights; |
|  |  |  |
|  | ● | our ability to attract and retain key officers and employees, and the continued involvement of Mahmud Haq as Executive Chairman and A. Hadi Chaudhry as Chief Executive Officer and President, all of which are critical to our ongoing operations, growing our business and integrating of our newly acquired businesses; |
|  |  |  |
|  | ● | our ability to comply with covenants contained in our credit agreement with our senior secured lender, Silicon Valley Bank and other future debt facilities; |
|  |  |  |
|  | ● | our ability to pay our monthly preferred dividends to the holders of our Series A and Series B preferred stock; |
|  |  |  |
|  | ● | our ability to compete with other companies developing products and selling services competitive with ours, and who may have greater resources and name recognition than we have; |
|  |  |  |
|  | ● | our ability to respond to the uncertainty resulting from the ongoing COVID-19 pandemic and the impact it may have on our operations, the demand for our services, and economic activity in general; and |
|  |  |  |
|  | ● | our ability to keep and increase market acceptance of our products and services. |

*Although we believe that the expectations reflected in the forward-looking statements contained in this Quarterly Report on Form 10-Q are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of such forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this Quarterly Report on Form 10-Q.*

*You should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.*

|  |
| --- |
| 2 |

**PART I. FINANCIAL INFORMATION**

Item 1. Consolidated Financial Statements

**CARECLOUD, INC.**

**CONSOLIDATED BALANCE SHEETS**

($ in thousands, except share and per share amounts)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | **(Unaudited)** | |  |  |  | |  |
| ASSETS |  |  |  |  |  |  |  |  |
| Current assets: |  |  |  |  |  |  |  |  |
| Cash |  | $ | 9,136 |  |  | $ | 9,340 |  |
| Restricted cash |  |  | 1,000 |  |  |  | 1,000 |  |
| Accounts receivable - net of allowance for doubtful accounts of $490 and $537 at March 31, 2022 and December 31, 2021, respectively |  |  | 18,493 |  |  |  | 17,006 |  |
| Contract asset |  |  | 4,645 |  |  |  | 4,725 |  |
| Inventory |  |  | 417 |  |  |  | 503 |  |
| Current assets - related party |  |  | 16 |  |  |  | 13 |  |
| Prepaid expenses and other current assets |  |  | 3,050 |  |  |  | 2,972 |  |
| Total current assets |  |  | 36,757 |  |  |  | 35,559 |  |
| Property and equipment - net |  |  | 5,396 |  |  |  | 5,404 |  |
| Operating lease right-of-use assets |  |  | 6,507 |  |  |  | 6,940 |  |
| Intangible assets - net |  |  | 30,487 |  |  |  | 30,778 |  |
| Goodwill |  |  | 61,186 |  |  |  | 61,186 |  |
| Other assets |  |  | 882 |  |  |  | 981 |  |
| TOTAL ASSETS |  | $ | 141,215 |  |  | $ | 140,848 |  |
| LIABILITIES AND SHAREHOLDERS’ EQUITY |  |  |  |  |  |  |  |  |
| Current liabilities: |  |  |  |  |  |  |  |  |
| Accounts payable |  | $ | 5,833 |  |  | $ | 5,948 |  |
| Accrued compensation |  |  | 2,857 |  |  |  | 4,251 |  |
| Accrued expenses |  |  | 5,998 |  |  |  | 5,091 |  |
| Operating lease liability (current portion) |  |  | 3,803 |  |  |  | 3,963 |  |
| Deferred revenue (current portion) |  |  | 1,140 |  |  |  | 1,085 |  |
| Deferred payroll taxes |  |  | 934 |  |  |  | 934 |  |
| Notes payable (current portion) |  |  | 95 |  |  |  | 344 |  |
| Contingent consideration (current portion) |  |  | 2,490 |  |  |  | 3,090 |  |
| Dividend payable |  |  | 3,950 |  |  |  | 3,856 |  |
| Consideration payable |  |  | 1,000 |  |  |  | 1,000 |  |
| Total current liabilities |  |  | 28,100 |  |  |  | 29,562 |  |
| Notes payable |  |  | 18 |  |  |  | 20 |  |
| Borrowings under line of credit |  |  | 6,000 |  |  |  | 8,000 |  |
| Operating lease liability |  |  | 3,929 |  |  |  | 4,545 |  |
| Deferred revenue |  |  | 390 |  |  |  | 341 |  |
| Deferred tax liability |  |  | 485 |  |  |  | 449 |  |
| Total liabilities |  |  | 38,922 |  |  |  | 42,917 |  |
| COMMITMENTS AND CONTINGENCIES (NOTE 8) |  |  | — |  |  |  | — |  |
| SHAREHOLDERS’ EQUITY: |  |  |  |  |  |  |  |  |
| Preferred stock $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 4,521,546 and 5,299,227 shares at March 31, 2022 and December 31, 2021, respectively. Series B, issued and outstanding 1,150,372 shares at March 31, 2022 |  |  | 6 |  |  |  | 5 |  |
| Common stock, $0.001 par value - authorized 29,000,000 shares. Issued 15,803,450 and 15,657,641 shares at March 31, 2022 and December 31, 2021, respectively. Outstanding 15,062,651 and 14,916,842 shares at March 31, 2022 and December 31, 2021, respectively. |  |  | 16 |  |  |  | 16 |  |
| Additional paid-in capital |  |  | 134,855 |  |  |  | 131,379 |  |
| Accumulated deficit |  |  | (29,913 | ) |  |  | (31,053 | ) |
| Accumulated other comprehensive loss |  |  | (2,009 | ) |  |  | (1,754 | ) |
| Less: 740,799 common shares held in treasury, at cost at March 31, 2022 and December 31, 2021 |  |  | (662 | ) |  |  | (662 | ) |
| Total shareholders’ equity |  |  | 102,293 |  |  |  | 97,931 |  |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |  | $ | 141,215 |  |  | $ | 140,848 |  |

See notes to consolidated financial statements.

|  |
| --- |
| 3 |

**CARECLOUD, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)**

**FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021**

($ in thousands, except share and per share amounts)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | **March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
| NET REVENUE |  | $ | 35,341 |  |  | $ | 29,768 |  |
| OPERATING EXPENSES: |  |  |  |  |  |  |  |  |
| Direct operating costs |  |  | 22,673 |  |  |  | 18,060 |  |
| Selling and marketing |  |  | 2,384 |  |  |  | 1,890 |  |
| General and administrative |  |  | 5,585 |  |  |  | 5,624 |  |
| Research and development |  |  | 985 |  |  |  | 2,026 |  |
| Change in contingent consideration |  |  | (600 | ) |  |  | — |  |
| Depreciation and amortization |  |  | 2,940 |  |  |  | 2,831 |  |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 158 |  |  |  | 1,018 |  |
| Total operating expenses |  |  | 34,125 |  |  |  | 31,449 |  |
| OPERATING INCOME (LOSS) |  |  | 1,216 |  |  |  | (1,681 | ) |
| OTHER: |  |  |  |  |  |  |  |  |
| Interest income |  |  | 5 |  |  |  | 15 |  |
| Interest expense |  |  | (100 | ) |  |  | (79 | ) |
| Other income (expense) - net |  |  | 83 |  |  |  | (220 | ) |
| INCOME (LOSS) BEFORE PROVISION (BENEFIT) FOR INCOME TAXES |  |  | 1,204 |  |  |  | (1,965 | ) |
| Income tax provision (benefit) |  |  | 64 |  |  |  | (1 | ) |
| NET INCOME (LOSS) |  | $ | 1,140 |  |  | $ | (1,964 | ) |
|  |  |  |  |  |  |  |  |  |
| Preferred stock dividend |  |  | 4,037 |  |  |  | 3,128 |  |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS |  | $ | (2,897 | ) |  | $ | (5,092 | ) |
|  |  |  |  |  |  |  |  |  |
| Net loss per common share: basic and diluted |  | $ | (0.19 | ) |  | $ | (0.36 | ) |
| Weighted-average common shares used to compute basic and diluted loss per share |  |  | 14,992,147 |  |  |  | 14,084,749 |  |

See notes to consolidated financial statements.

|  |
| --- |
| 4 |

**CARECLOUD, INC.**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)**

**FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021**

($ in thousands)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | **March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
| NET INCOME (LOSS) |  | $ | 1,140 |  |  | $ | (1,964 | ) |
| OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX |  |  |  |  |  |  |  |  |
| Foreign currency translation adjustment (a) |  |  | (255 | ) |  |  | 345 |  |
| COMPREHENSIVE INCOME (LOSS) |  | $ | 885 |  |  | $ | (1,619 | ) |

|  |  |
| --- | --- |
| (a) | No tax effect has been recorded as the Company recorded a valuation allowance against the tax benefit from its foreign currency translation adjustments. |

See notes to consolidated financial statements.

|  |
| --- |
| 5 |

**CARECLOUD, INC.**

**CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)**

**FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND MARCH 31, 2021**

($ in thousands, except for number of shares)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
|  |  | **Preferred Stock Series A** | | | | | |  |  | **Preferred Stock Series B** | | | | | |  |  | **Common Stock** | | | | | |  |  | **Additional Paid-in** | |  |  | **Accumulated** | |  |  | **Accumulated Other Comprehensive** | |  |  | **Treasury (Common)** | |  |  | **Total Shareholders’** | |  |
|  |  | **Shares** | |  |  | **Amount** | |  |  | **Shares** | |  |  | **Amount** | |  |  | **Shares** | |  |  | **Amount** | |  |  | **Capital** | |  |  | **Deficit** | |  |  | **Loss** | |  |  | **Stock** | |  |  | **Equity** | |  |
| Balance - January 1, 2022 |  |  | 5,299,227 |  |  | $ | 5 |  |  |  | — |  |  | $ | — |  |  |  | 15,657,641 |  |  | $ | 16 |  |  | $ | 131,379 |  |  | $ | (31,053 | ) |  | $ | (1,754 | ) |  | $ | (662 | ) |  | $ | 97,931 |  |
| Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,140 |  |  |  | — |  |  |  | — |  |  |  | 1,140 |  |
| Foreign currency translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (255 | ) |  |  | — |  |  |  | (255 | ) |
| Issuance of stock under the equity incentive plan |  |  | 22,319 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 145,809 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |
| Stock-based compensation, net of cash settlements |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 887 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 887 |  |
| Redemption of Series A Preferred Stock |  |  | (800,000 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (20,000 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (20,000 | ) |
| Issuance of Series B Preferred Stock |  |  | — |  |  |  | — |  |  |  | 1,150,372 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 26,637 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 26,638 |  |
| Stock issuance costs |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (11 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (11 | ) |
| Preferred stock dividends |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,037 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4,037 | ) |
| Balance - March 31, 2022 |  |  | 4,521,546 |  |  | $ | 5 |  |  |  | 1,150,372 |  |  | $ | 1 |  |  |  | 15,803,450 |  |  | $ | 16 |  |  | $ | 134,855 |  |  | $ | (29,913 | ) |  | $ | (2,009 | ) |  | $ | (662 | ) |  | $ | 102,293 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Balance - January 1, 2021 |  |  | 5,475,279 |  |  | $ | 5 |  |  |  | — |  |  | $ | — |  |  |  | 14,121,044 |  |  | $ | 14 |  |  | $ | 136,781 |  |  | $ | (33,889 | ) |  | $ | (1,004 | ) |  | $ | (662 | ) |  | $ | 101,245 |  |
| Balance |  |  | 5,475,279 |  |  | $ | 5 |  |  |  | — |  |  | $ | — |  |  |  | 14,121,044 |  |  | $ | 14 |  |  | $ | 136,781 |  |  | $ | (33,889 | ) |  | $ | (1,004 | ) |  | $ | (662 | ) |  | $ | 101,245 |  |
| Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,964 | ) |  |  | — |  |  |  | — |  |  |  | (1,964 | ) |
| Net income (loss) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,964 | ) |  |  | — |  |  |  | — |  |  |  | (1,964 | ) |
| Foreign currency translation adjustment |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 345 |  |  |  | — |  |  |  | 345 |  |
| Issuance of stock under the equity incentive plan |  |  | 27,682 |  |  |  | 1 |  |  |  | — |  |  |  | — |  |  |  | 161,545 |  |  |  | — |  |  |  | (1 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |
| Stock-based compensation, net of cash settlements |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 623 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 623 |  |
| Stock issuance costs |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (43 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (43 | ) |
| Exercise of common stock warrants |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 858,000 |  |  |  | 1 |  |  |  | 6,434 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 6,435 |  |
| Preferred stock dividends |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (3,128 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (3,128 | ) |
| Balance - March 31, 2021 |  |  | 5,502,961 |  |  | $ | 6 |  |  |  | — |  |  | $ | — |  |  |  | 15,140,589 |  |  | $ | 15 |  |  | $ | 140,666 |  |  | $ | (35,853 | ) |  | $ | (659 | ) |  | $ | (662 | ) |  | $ | 103,513 |  |
| Balance |  |  | 5,502,961 |  |  | $ | 6 |  |  |  | — |  |  | $ | — |  |  |  | 15,140,589 |  |  | $ | 15 |  |  | $ | 140,666 |  |  | $ | (35,853 | ) |  | $ | (659 | ) |  | $ | (662 | ) |  | $ | 103,513 |  |

For all periods presented, the preferred stock dividends were paid monthly at the rate of $2.75 and $2.19 for Series A and Series B, respectively, per share per annum.

See notes to consolidated financial statements.

|  |
| --- |
| 6 |

**CARECLOUD, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

**FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021**

($ in thousands)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
| OPERATING ACTIVITIES: |  |  |  |  |  |  |  |  |
| Net income (loss) |  | $ | 1,140 |  |  | $ | (1,964 | ) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |  |  |  |  |  |  |
| Depreciation and amortization |  |  | 3,080 |  |  |  | 2,945 |  |
| Lease amortization |  |  | 832 |  |  |  | 728 |  |
| Deferred revenue |  |  | 104 |  |  |  | 32 |  |
| Provision for doubtful accounts |  |  | 131 |  |  |  | 192 |  |
| Provision (benefit) for deferred income taxes |  |  | 36 |  |  |  | (36 | ) |
| Foreign exchange (gain) loss |  |  | (52 | ) |  |  | 143 |  |
| Interest accretion |  |  | 168 |  |  |  | 139 |  |
| Gain on sale of assets |  |  | (6 | ) |  |  | — |  |
| Stock-based compensation expense |  |  | 887 |  |  |  | 1,267 |  |
| Change in contingent consideration |  |  | (600 | ) |  |  | — |  |
| Changes in operating assets and liabilities, net of businesses acquired: |  |  |  |  |  |  |  |  |
| Accounts receivable |  |  | (1,618 | ) |  |  | (522 | ) |
| Contract asset |  |  | 80 |  |  |  | (270 | ) |
| Inventory |  |  | 86 |  |  |  | 20 |  |
| Other assets |  |  | (97 | ) |  |  | (10 | ) |
| Accounts payable and other liabilities |  |  | (1,084 | ) |  |  | (1,706 | ) |
| Net cash provided by operating activities |  |  | 3,087 |  |  |  | 958 |  |
| INVESTING ACTIVITIES: |  |  |  |  |  |  |  |  |
| Purchase of property and equipment |  |  | (544 | ) |  |  | (695 | ) |
| Capitalized software |  |  | (2,253 | ) |  |  | (1,524 | ) |
| Net cash used in investing activities |  |  | (2,797 | ) |  |  | (2,219 | ) |
| FINANCING ACTIVITIES: |  |  |  |  |  |  |  |  |
| Preferred stock dividends paid |  |  | (3,943 | ) |  |  | (3,592 | ) |
| Settlement of tax withholding obligations on stock issued to employees |  |  | (775 | ) |  |  | (1,402 | ) |
| Repayments of notes payable, net |  |  | (251 | ) |  |  | (241 | ) |
| Stock issuance costs |  |  | (11 | ) |  |  | (43 | ) |
| Proceeds from exercise of warrants |  |  | — |  |  |  | 6,435 |  |
| Proceeds from issuance of Series B Preferred Stock, net of expenses |  |  | 26,638 |  |  |  | — |  |
| Redemption of Series A Preferred Stock |  |  | (20,000 | ) |  |  | — |  |
| Proceeds from line of credit |  |  | 8,500 |  |  |  | — |  |
| Repayment of line of credit |  |  | (10,500 | ) |  |  | — |  |
| Net cash (used in) provided by financing activities |  |  | (342 | ) |  |  | 1,157 |  |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH |  |  | (152 | ) |  |  | 174 |  |
| NET (DECREASE) INCREASE IN CASH |  |  | (204 | ) |  |  | 70 |  |
| CASH AND RESTRICTED CASH - Beginning of the period |  |  | 10,340 |  |  |  | 20,925 |  |
| CASH AND RESTRICTED CASH - End of the period |  | $ | 10,136 |  |  | $ | 20,995 |  |
| SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES: |  |  |  |  |  |  |  |  |
| Dividends declared, not paid |  | $ | 3,950 |  |  | $ | 3,777 |  |
| SUPPLEMENTAL INFORMATION - Cash paid during the period for: |  |  |  |  |  |  |  |  |
| Income taxes |  | $ | — |  |  | $ | 59 |  |
| Interest |  | $ | 40 |  |  | $ | 16 |  |

See notes to consolidated financial statements.

|  |
| --- |
| 7 |

**CARECLOUD, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**AS OF AND FOR THE THREE MONTHS ENDED MARCH 31, 2022**

**AND 2021 (UNAUDITED)**

**1. ORGANIZATION AND BUSINESS**

CareCloud, Inc., formerly MTBC, Inc. (“CareCloud”, and together with its consolidated subsidiaries, the “Company,” “we,” “us” and/or “our”) is a healthcare information technology company that provides a full suite of proprietary cloud-based solutions, together with related business services, to healthcare providers and hospitals throughout the United States. The Company’s integrated services are designed to help customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. Our Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health record (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems. CareCloud has its corporate offices in Somerset, New Jersey and maintains client support teams throughout the U.S., and offshore offices in Pakistan and Azad Jammu and Kashmir, a region administered by Pakistan (the “Pakistan Offices”), and in Sri Lanka.

CareCloud was founded in 1999 under the name Medical Transcription Billing, Corp. and incorporated under the laws of the State of Delaware in 2001. In 2004, the Company formed MTBC Private Limited (or “MTBC Pvt. Ltd.”), a 99.9% majority-owned subsidiary of CareCloud based in Pakistan. The remaining 0.1% of the shares of MTBC Pvt. Ltd. is owned by the founder and Executive Chairman of CareCloud. In 2016, the Company formed MTBC Acquisition Corp. (“MAC”), a Delaware corporation, in connection with its acquisition of substantially all of the assets of MediGain, LLC and its subsidiary, Millennium Practice Management Associates, LLC (together “MediGain”). MAC has a wholly owned subsidiary in Sri Lanka, RCM MediGain Colombo, Pvt. Ltd. In May 2018, the Company formed CareCloud Practice Management, Corp. (“CPM”), a Delaware corporation, to operate the medical practice management business acquired from Orion Healthcorp.

In January 2020, the Company purchased CareCloud Corporation, a company whose name we took. That company is now known as CareCloud Health, Inc. (“CCH”). In June 2020, the Company purchased Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively “Meridian” and sometimes referred to as “Meridian Medical Management”).

During March 2021, the Company formed a new wholly-owned subsidiary, CareCloud Acquisition, Corp. (“CAC”). In June 2021, CAC purchased certain assets and assumed certain liabilities of MedMatica Consulting Associates Inc., (“MedMatica”) and purchased the stock of Santa Rosa Staffing, Inc., (“SRS”). The assets and liabilities of MedMatica were merged into SRS and the company was renamed medSR, Inc. (“medSR”). See Note 3.

**2. BASIS OF PRESENTATION**

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 8-03. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the Company’s financial position as of March 31, 2022, the results of operations for the three months ended March 31, 2022 and 2021 and cash flows for the three months ended March 31, 2022 and 2021. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates.

|  |
| --- |
| 8 |

The accompanying unaudited consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2021, which are included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 14, 2022.

***Recent Accounting Pronouncements*** — From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently adopted and recently issued accounting pronouncements will not have a material impact on our consolidated financial position, results of operations and cash flows.

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments.* The guidance in Accounting Standards Update (“ASU”) 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. It will apply to all entities. For trade receivables, loans and held-to-maturity debt securities, entities will be required to estimate lifetime expected credit losses. This may result in the earlier recognition of credit losses. In November 2019, the FASB issued ASU No. 2019-10, which delays this standard’s effective date for SEC smaller reporting companies to the fiscal years beginning on or after December 15, 2022. The Company is in the process of determining if this update will have a significant impact on the consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, *Simplifying the Accounting for Income Taxes*. This ASU simplifies accounting for income taxes to reduce complexity in the accounting standards. The amendments consist of the removal of certain exceptions to the general principles of ASC 740 and some additional simplifications. The amendments are effective for public business entities for fiscal years beginning after December 15, 2020. The Company adopted this guidance effective January 1, 2021. There was no impact on the consolidated financial statements as a result of this standard.

In August 2020, the FASB issued ASU 2020-06, *Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40).* This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments are not required to be implemented until 2022 for public entities. There was no impact on the consolidated financial statements as a result of this standard.

In October 2021, the FASB issued ASU 2021-08, *Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.* The amendments in this update require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination. The amendments are effective for public business entities for fiscal years beginning after December 15, 2022. The Company is in the process of determining if this update will have a significant impact on the consolidated financial statements.

**3. ACQUISITIONS**

**2021 Acquisition**

On June 1, 2021, CAC entered into an Asset and Stock Purchase Agreement (“Purchase Agreement”) with MedMatica and its sole shareholder. Pursuant to the Purchase Agreement, CAC acquired (i) all of the issued and outstanding capital stock of SRS, a Delaware corporation, and (ii) all of the MedMatica assets that were used in MedMatica’s and SRS’ business. Certain MedMatica liabilities were also assumed under the Purchase Agreement. The total cash consideration was $10 million plus a working capital adjustment of approximately $3.8 million. The Purchase Agreement also provides that if during the 18-month period commencing on June 1, 2021 (the “Earn-Out Period”), certain EBITDA and revenue targets with respect to the assets and capital stock purchased under the Purchase Agreement are achieved, then CAC shall pay MedMatica an earn-out up to a maximum of $8 million. Further, if during the Earn-Out Period, certain additional and increased EBITDA and revenue targets with respect to the assets and capital stock purchased under the Purchase Agreement are achieved, then CAC shall pay MedMatica an additional earn-out, up to a maximum of $5 million.

|  |
| --- |
| 9 |

MedMatica and SRS are in the business of providing a broad range of specialty consulting services to hospitals and large healthcare groups, including certain consulting services related to healthcare IT application services and implementations, medical practice management, and revenue cycle management. The acquisition has been accounted for as a business combination.

A summary of the total consideration is as follows:

 SUMMARY OF TOTAL CONSIDERATION ON BUSINESS CONSIDERATION

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **medSR Purchase Price** |  |  | |  |
|  |  | ($ in thousands) | |  |
| Cash |  | $ | 12,261 |  |
| Amounts held in escrow |  |  | 1,571 |  |
| Contingent consideration |  |  | 5,605 |  |
| **Total purchase price** |  | **$** | **19,437** |  |

The Company engaged a third party valuation specialist to assist the Company in valuing the assets acquired and liabilities assumed from MedMatica. The following table summarizes the purchase price allocation.

 SCHEDULE OF ASSETS ACQUIRED AND LIABILITIES ASSUMED

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | ($ in thousands) | |  |
| Accounts receivable |  | $ | 2,696 |  |
| Receivable from seller |  |  | 227 |  |
| Prepaid expenses |  |  | 102 |  |
| Unbilled receivables |  |  | 2,491 |  |
| Property and equipment |  |  | 84 |  |
| Customer relationships |  |  | 3,100 |  |
| Acquired backlog |  |  | 490 |  |
| Goodwill |  |  | 11,931 |  |
| Accounts payable |  |  | (539 | ) |
| Accrued expenses & compensation |  |  | (1,125 | ) |
| Deferred revenue |  |  | (20 | ) |
| **Total purchase price allocation** |  | **$** | **19,437** |  |

The acquired accounts receivable is recorded at fair value, which represents amounts that have subsequently been paid or were expected to be paid by clients. The fair value of customer relationships was based on the estimated discounted cash flows generated by these intangibles. The goodwill represents the Company’s ability to have an expanded local presence in additional markets and operational synergies that we expect to achieve that would not be available to other market participants. The goodwill from this acquisition is deductible ratably for income tax purposes over fifteen years. The purchase agreement provides that if revenue and EBITDA over the next 18 months exceeds certain specified amounts, there will be an earn-out payment to the seller equal to such excess, up to $13 million. It was estimated that the probable payment will be approximately $5.6 million and this amount was recorded as part of the purchase price allocation as contingent consideration. At March 31, 2022 and December 31, 2021, the Company determined that the fair value of the contingent consideration was approximately $2.5 million and $3.1 million, respectively, based in part on the actual operating results since the acquisition. The difference in the contingent consideration between December 31, 2021 and March 31, 2022 has been recorded as a change in contingent consideration in the consolidated statements of operations.

As part of the acquisition, $1.5 million of the purchase price was held in escrow, which represented $500,000 to be paid upon the achievement of agreed-upon revenue and backlog milestones, and the balance to be held for up to 18 months to satisfy certain indemnification obligations. During the third quarter of 2021, the initial portion of the escrow was settled whereby $250,000 was paid to the seller and $250,000 was offset against the working capital adjustment. An additional $71,000 that was held in escrow was also paid. The balance of the $1.0 million escrow is included in consideration payable and restricted cash in the consolidated balance sheets at December 31, 2021 and March 31, 2022. Approximately $12.3 million in cash was paid at closing.

|  |
| --- |
| 10 |

The weighted-average amortization period of the acquired intangible assets is approximately three years.

Revenue earned from the clients obtained from the medSR acquisition on June 1, 2021 was approximately $7.3 million for the three months ended March 31, 2022.

The medSR acquisition added additional clients to the Company’s customer base and, similar to previous acquisitions, broadened the Company’s presence in the healthcare information technology industry through expansion of its customer base and by increasing available customer relationship resources and specialized trained staff.

**Pro forma financial information (Unaudited)**

The unaudited pro forma information below represents the consolidated results of operations as if the medSR acquisition occurred on January 1, 2021. The pro forma information has been included for comparative purposes and is not indicative of results of operations that the Company would have had if the acquisition occurred on the above date, nor is it necessarily indicative of future results. The unaudited pro forma information reflects material, non-recurring pro forma adjustments directly attributable to the business combination. The difference between the actual revenue and the pro forma revenue is approximately $9.7 million of additional revenue recorded by medSR for the three months ended March 31, 2021. Other differences arise from amortizing purchased intangibles using the double declining balance method.

 SCHEDULE OF BUSINESS ACQUISITION PRO FORMA INFORMATION

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands except per share amounts) | | | | | |  |
| Total revenue |  | $ | 35,341 |  |  | $ | 39,455 |  |
| Net income (loss) |  | $ | 1,237 |  |  | $ | (1,286 | ) |
| Net loss attributable to common shareholders |  | $ | (2,800 | ) |  | $ | (4,414 | ) |
| Net loss per common share |  | $ | (0.19 | ) |  | $ | (0.31 | ) |

**4. GOODWILL AND INTANGIBLE ASSETS-NET**

Goodwill consists of the excess of the purchase price over the fair value of identifiable net assets of businesses acquired. The following is the summary of the changes to the carrying amount of goodwill for the three months ended March 31, 2022 and the year ended December 31, 2021:

 SCHEDULE OF INTANGIBLE ASSETS AND GOODWILL

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended** | |  |  | **Year Ended** | |  |
|  |  | **March 31, 2022** | |  |  | **December 31, 2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Beginning gross balance |  | $ | 61,186 |  |  | $ | 49,291 |  |
| Acquisition, net of adjustments |  |  | — |  |  |  | 11,895 |  |
| Ending gross balance |  | $ | 61,186 |  |  | $ | 61,186 |  |

|  |
| --- |
| 11 |

Intangible assets include customer contracts and relationships and covenants not-to-compete acquired in connection with acquisitions, as well as trademarks acquired and software costs. Intangible assets – net as of March 31, 2022, and December 31, 2021 consist of the following:

 SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31, 2022** | |  |  | **December 31, 2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Contracts and relationships acquired |  | $ | 47,597 |  |  | $ | 47,597 |  |
| Capitalized software |  |  | 15,387 |  |  |  | 13,196 |  |
| Non-compete agreements |  |  | 1,236 |  |  |  | 1,236 |  |
| Other intangible assets |  |  | 8,396 |  |  |  | 8,396 |  |
| Total intangible assets |  |  | 72,616 |  |  |  | 70,425 |  |
| Less: Accumulated amortization |  |  | 42,129 |  |  |  | 39,647 |  |
| Intangible assets - net |  | $ | 30,487 |  |  | $ | 30,778 |  |

Other intangible assets primarily represent software costs. Amortization expense was approximately $2.5 million and $2.4 million for the three months ended March 31, 2022 and 2021, respectively. The weighted-average amortization period is three years.

As of March 31, 2022, future amortization scheduled to be expensed is as follows:

 SCHEDULE OF FINITE-LIVED INTANGIBLE ASSETS, FUTURE AMORTIZATION EXPENSE

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Years ending December 31,** |  | ($ in thousands) | |  |
| 2022 (nine months) |  | $ | 10,272 |  |
| 2023 |  |  | 10,786 |  |
| 2024 |  |  | 6,765 |  |
| 2025 |  |  | 1,314 |  |
| 2026 |  |  | 300 |  |
| Thereafter |  |  | 1,050 |  |
| Total |  | $ | 30,487 |  |

**5. NET LOSS PER COMMON SHARE**

The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per share for the three months ended March 31, 2022 and 2021:

 SCHEDULE OF LOSSES PER SHARE, BASIC AND DILUTED

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | **March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands, except share and per share amounts) | | | | | |  |
| Basic and Diluted: |  |  |  |  |  |  |  |  |
| Net loss attributable to common shareholders |  | $ | (2,897 | ) |  | $ | (5,092 | ) |
| Weighted-average common shares used to compute basic and diluted loss per share |  |  | 14,992,147 |  |  |  | 14,084,749 |  |
| Net loss attributable to common shareholders per share - basic and diluted |  | $ | (0.19 | ) |  | $ | (0.36 | ) |

All unvested restricted stock units (“RSUs”) and unexercised warrants have been excluded from the above calculations as they were anti-dilutive. Vested RSUs, vested restricted shares and exercised warrants have been included in the above calculations.

|  |
| --- |
| 12 |

**6. DEBT**

*SVB* — During October 2017, the Company opened a revolving line of credit with Silicon Valley Bank (“SVB”) under a three-year agreement. The SVB credit facility is a secured revolving line of credit where borrowings are based on a formula of 200% of repeatable revenue adjusted by an annualized attrition rate as defined in the credit agreement. During the third quarter of 2018, the credit line was increased from $5 million to $10 million and the term was extended for an additional year. During the third quarter of 2021, the credit line was further increased to $20 million and the term was extended for another year. As of March 31, 2022, there was $6 million borrowed under the credit facility, which was repaid in early April. Interest on the SVB revolving line of credit is currently charged at the prime rate plus 1.50% with a minimum rate of 6.50%. There is also a fee of one-half of 1% annually for the unused portion of the credit line. The debt is secured by all of the Company’s domestic assets and 65% of the shares in its offshore subsidiaries. Future acquisitions are subject to approval by SVB.

In connection with the original SVB debt agreement, the Company paid SVB approximately $50,000 of fees upfront and issued warrants for SVB to purchase 125,000 shares of its common stock, and committed to pay an annual anniversary fee of $50,000 a year. Based on the terms in the original SVB credit agreement, these warrants have a strike price equal to $3.92. They have a five-year exercise window and net exercise rights, and were valued at $3.12 per warrant. As a result of the revision in the SVB credit line, which increased the credit line from $5 million to $10 million and reduced the interest rate by 25 basis points, the Company paid approximately $50,000 of fees upfront and issued an additional 28,489 warrants, with a strike price equal to $5.26, a five-year exercise window and net exercise rights. The additional warrants were valued at $3.58 per warrant. The SVB credit agreement contains various covenants and conditions governing the revolving line of credit. These covenants include a minimum level of adjusted EBITDA and a minimum liquidity ratio. At March 31, 2022 and 2021, the Company was in compliance with all covenants.

During January 2022, the agreement with SVB was modified to allow the Company to issue Series B Preferred Stock and pay monthly dividends on this stock, to use a portion of the offering proceeds to redeem a portion of the Series A Preferred Stock that is outstanding and to allow for the potential exchange of shares of Series A Preferred Stock for Series B Preferred Stock.

*Vehicle Financing Notes* — The Company financed certain vehicle purchases both in the United States and in Pakistan. The vehicle financing notes have three to six year terms and were issued at current market rates.

*Insurance Financing* — The Company finances certain insurance purchases over the term of the policy life. The interest rate charged is currently 4.15%.

**7. LEASES**

We determine if an arrangement is a lease at inception. We have operating leases for office and temporary living space as well as for some office equipment. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liability and non-current operating lease liability in our consolidated balance sheets as of March 31, 2022 and December 31, 2021. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to our bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease terms include options to extend the lease when we believe that we may want the right to exercise that option. Leases with a term of less than 12 months are not recorded in the consolidated balance sheets. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the lease and non-lease components as a single lease component. Some leases include escalation clauses and termination options that are factored in the determination of the lease payments when appropriate.

|  |
| --- |
| 13 |

If a lease is modified after the effective date, the operating lease ROU asset and liability are re-measured using the current incremental borrowing rate. We review our incremental borrowing rate for our portfolio of leases on a quarterly basis. During the three months ended March 31, 2022 and 2021, there were approximately $263,000 and $243,000, respectively, of unoccupied lease charges for two of the Company’s facilities. There were no lease impairments or restructuring charges during the three months ended March 31, 2022 and 2021. During the quarter ended March 31, 2022, there was a gain on lease termination of approximately $105,000. During the three months ended March 31, 2021, the Company recorded approximately $775,000 of impairment charges on a vendor contract.

Lease expense is included in direct operating costs and general and administrative expenses in the consolidated statements of operations based on the nature of the expense. As of March 31, 2022, we had 34 leased properties, five in Medical Practice Management and 29 in Healthcare IT, with remaining terms ranging from less than one year to fifteen years. Our lease terms are determined taking into account lease renewal options, the Company’s anticipated operating plans and leases that are on a month-to-month basis. The Company also has some related party leases – see Note 9.

The components of lease expense were as follows:

 SCHEDULE OF LEASE EXPENSE

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Operating lease cost |  | $ | 972 |  |  | $ | 1,057 |  |
| Short-term lease cost |  |  | 40 |  |  |  | 22 |  |
| Variable lease cost |  |  | 9 |  |  |  | 6 |  |
| Total- net lease cost |  | $ | 1,021 |  |  | $ | 1,085 |  |

Short-term lease cost represents leases that were not capitalized as the lease term as of the later of January 1, 2022 or the beginning of the lease was less than 12 months. Variable lease costs include utilities, real estate taxes and common area maintenance costs.

Supplemental balance sheet information related to leases is as follows:

 SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31, 2022** | |  |  | **December 31, 2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Operating leases: |  |  |  |  |  |  |  |  |
| Operating lease ROU assets, net |  | $ | 6,507 |  |  | $ | 6,940 |  |
|  |  |  |  |  |  |  |  |  |
| Current operating lease liabilities |  | $ | 3,803 |  |  | $ | 3,963 |  |
| Non-current operating lease liabilities |  |  | 3,929 |  |  |  | 4,545 |  |
| Total operating lease liabilities |  | $ | 7,732 |  |  | $ | 8,508 |  |
|  |  |  |  |  |  |  |  |  |
| Operating leases: |  |  |  |  |  |  |  |  |
| ROU assets |  | $ | 7,366 |  |  | $ | 10,535 |  |
| Asset lease expense |  |  | (832 | ) |  |  | (3,574 | ) |
| Foreign exchange loss |  |  | (27 | ) |  |  | (21 | ) |
| ROU assets, net |  | $ | 6,507 |  |  | $ | 6,940 |  |
|  |  |  |  |  |  |  |  |  |
| Weighted average remaining lease term (in years): |  |  |  |  |  |  |  |  |
| Operating leases |  |  | 4.54 |  |  |  | 4.26 |  |
| Weighted average discount rate: |  |  |  |  |  |  |  |  |
| Operating leases |  |  | 6.74 | % |  |  | 6.76 | % |

|  |
| --- |
| 14 |

Supplemental cash flow and other information related to leases is as follows:

SCHEDULE OF SUPPLEMENTAL CASH FLOW AND OTHER INFORMATION RELATED TO LEASES

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  | |  |  |  | |  |
| Operating cash flows from operating leases |  | $ | 1,212 |  |  | $ | 1,396 |  |
|  |  |  |  |  |  |  |  |  |
| ROU assets obtained in exchange for lease liabilities: |  |  |  |  |  |  |  |  |
| Operating leases, net of impairment and terminations |  | $ | 427 |  |  | $ | 211 |  |

Maturities of lease liabilities are as follows:

 SCHEDULE OF MATURITIES OF LEASE LIABILITIES

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Operating leases - Years ending December 31,** |  | ($ in thousands) | |  |
| 2022 (nine months) |  | $ | 3,359 |  |
| 2023 |  |  | 2,366 |  |
| 2024 |  |  | 1,075 |  |
| 2025 |  |  | 514 |  |
| 2026 |  |  | 232 |  |
| Thereafter |  |  | 1,756 |  |
| Total lease payments |  |  | 9,302 |  |
| Less: imputed interest |  |  | (1,570 | ) |
| Total lease obligations |  |  | 7,732 |  |
| Less: current obligations |  |  | (3,803 | ) |
| Long-term lease obligations |  | $ | 3,929 |  |

**8. COMMITMENTS AND CONTINGENCIES**

**Legal Proceedings** — On May 30, 2018, the Superior Court of New Jersey, Chancery Division, Somerset County (the “Chancery Court”) denied the Company’s and MTBC Acquisition Corp.’s (“MAC’s”) request to enjoin an arbitration proceeding demanded by Randolph Pain Relief and Wellness Center (“RPRWC”) related to RCM services provided by parties unaffiliated with the Company and MAC. On June 15, 2018, the Company and MAC filed an appeal of the Chancery Court’s decision with the New Jersey Superior Court, Appellate Division. On July 19, 2018, the Chancery Court ordered that the arbitration be stayed pending the Company’s and MAC’s appeal. On appeal, the Company and MAC contended they were never party to the billing services agreement giving rise to the arbitration claim, did not assume the obligations of Millennium Practice Management Associates, Inc. (“MPMA”) under such agreement, and any agreement to arbitrate disputes arising under such agreement did not apply to the Company or MAC as RPRWC terminated the agreement before the APA took effect. On January 30, 2019, the parties conducted oral arguments before the Appellate Court.

On April 23, 2019, the Appellate Division affirmed in part and reversed in part the trial court’s order. The Appellate Division upheld the portion of the trial court’s order requiring MAC to participate in the arbitration based on the trial court’s finding that MAC had assumed MPMA’s contractual responsibilities. The Appellate Division reversed the trial court’s order requiring the Company to participate in the arbitration on the grounds that insufficient facts had been provided by RPRWC from which the court could conclude the Company was required to participate in the arbitration. As a result, the Appellate Division remanded the issue of whether Company is required to participate in the arbitration back to the trial court for further proceedings.

|  |
| --- |
| 15 |

The parties completed discovery in the remanded matter on November 29, 2019, and thereafter both the Company and RPRWC filed cross-motions for summary judgment in their favor. On February 6, 2020, the Chancery Court denied RPRWC’s motion for summary judgment and granted the Company’s cross-motion for summary judgment. The Chancery Court held that the Company cannot be compelled to participate in the Arbitration. RPRWC has informed the Company that it does not intend to appeal the Chancery Court’s ruling and that it intends to move forward solely against MAC. On March 25, 2020, the Chancery Court lifted the stay of arbitration relative to RPRWC and MAC. In its arbitration demand RPRWC alleges that MPMA, a subsidiary of MediGain, LLC, breached the terms of the billing services agreement the parties had entered into and sought compensatory damages of $6.6 million and costs.

On May 28, 2020, the arbitrator handling the matter conducted a scheduling conference with the parties in order to establish deadlines for the parties to exchange discovery requests and responses. During the conference, the arbitrator directed RPRWC to produce statement of damages on which it bases its claim. RPRWC disclosed its statement of damages to MAC on June 12, 2020. RPRWC’s June 12, 2020 statement of damages increased its alleged damages from $6.6 million and costs to $20 million and costs. On July 24, 2020, RPRWC disclosed a declaration to MAC, in which RPRWC estimates its damages to be approximately $11 million plus costs. RPRWC then served expert reports in November 2021. Plaintiff’s expert analyzed only a minute portion of the claims alleged to have been mishandled and then extrapolated damages to be in the range of $9.8 million to $10.8 million; however, this is unrealistically based on an alleged 90-100% collection rate on charges. MAC has served an expert report refuting the methodology used by RPRWC’s expert, the allegations of mishandling and the calculated damages. This matter is currently being prepared for an arbitration hearing which is currently scheduled on several dates in June 2022.

While the allegations of breach of contract made by RPRWC are the subject of the ongoing legal proceedings, MAC believes RPRWC’s allegations lack merit on numerous grounds. The Company and MAC plan to vigorously defend against RPRWC’s claim and in the event of a loss, if any, they anticipate the loss to be substantially less than the amount claimed.

Through the CCH transaction, we acquired its software technology and related business, of which certain elements were, at the time of the acquisition, subject to a civil investigation to determine pre-acquisition compliance with certain federal regulatory requirements. This element was considered as part of the transaction as $4 million of the transaction’s consideration was held in escrow for the resolution of this investigation. Following the closing of the transaction, the Company continued to cooperate with the inquiry as CCH had historically done since the commencement of the investigation in July of 2018. The Company accrued $4.2 million to resolve this investigation, including the $4 million in escrow, which was recorded as an indemnification asset which is included in the consolidated balance sheets at December 31, 2020 in prepaid expenses and other current assets with an offsetting amount in accrued expenses. The Company settled the obligation in April 2021 substantially within the range covered by the escrowed funds.

From time to time, we may become involved in other legal proceedings arising in the ordinary course of our business. Including the proceedings described above, we are not presently a party to any legal proceedings that, in the opinion of our management, would individually or taken together have a material adverse effect on our business, consolidated results of operations, financial position or cash flows of the Company.

**9. RELATED PARTIES**

The Company had sales to a related party, a physician who is the wife of the Executive Chairman. Revenues from this customer were approximately $5,000 and $4,000 for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, and December 31, 2021, the receivable balance due from this customer was approximately $2,000 and $3,000, respectively.

The Company was a party to a nonexclusive aircraft dry lease agreement with Kashmir Air, Inc. (“KAI”), which was owned by the Executive Chairman. The Company recorded an expense of approximately $30,000 for the three months ended March 31, 2021. The lease for the aircraft was renewed as of April 1, 2021 and terminated on August 31, 2021. As of March 31, 2022, there was no liability outstanding to KAI.

|  |
| --- |
| 16 |

The Company leases its corporate offices in New Jersey, its temporary housing for its foreign visitors, a printing and mailing facility and its backup operations center in Bagh, Pakistan and an apartment for temporary housing in Dubai, the UAE, from the Executive Chairman. The related party rent expense for the three months ended March 31, 2022 and 2021 was approximately $51,000 and $47,000, respectively, and is included in direct operating costs and general and administrative expense in the consolidated statements of operations. During the three months ended March 31, 2022 and 2021, the Company spent approximately $288,000 and $289,000 to upgrade the related party leased facilities. Current assets-related party in the consolidated balance sheets includes security deposits related to the leases of the Company’s corporate offices in the amount of approximately $16,000 and $13,000 as of March 31, 2022 and December 31, 2021, respectively.

Included in the ROU asset at March 31, 2022 is approximately $438,000 applicable to the related party leases. Included in the current and non-current operating lease liability at March 31, 2022 is approximately $173,000 and $261,000, respectively, applicable to the related party leases.

Included in the ROU asset at December 31, 2021 is approximately $483,000 applicable to the related party leases. Included in the current and non-current operating lease liability at December 31, 2021 is approximately $174,000 and $305,000, respectively, applicable to the related party leases.

During 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of March 31, 2022, talkMD had not yet commenced operations.

**10. SHAREHOLDERS’ EQUITY**

During the current quarter, the Company sold 1,100,810 shares of 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (“Series B Preferred Stock”) and received net proceeds of approximately $25.5 million. The Series B Preferred Stock is listed on the Nasdaq Global Market under the symbol “MTBCO.” Dividends on the Series B Preferred Stock of approximately $2.19 annually per share are cumulative from the date of issue and are payable each month when, as and if declared by the Company’s Board of Directors. On March 18, 2022, the Company used a portion of the proceeds from selling Series B Preferred Stock and redeemed 800,000 shares of Series A Preferred Stock for $25.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date.

Commencing on February 15, 2024 and prior to February 15, 2025, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.75 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2025 and prior to February 15, 2026, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.50 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2026 and prior to February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.25 per share, plus all accrued and unpaid dividends to, but not including, the redemption date. On or after February 15, 2027, we may redeem, at our option, the Series B Preferred Stock, in whole or in part, at a cash redemption price of $25.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date.

The Company has the right to sell up to $35 million of its Series B Preferred Stock using an “at-the-market” facility (“ATM”). The underwriter receives 3% of the gross proceeds. During the first quarter of 2022, the Company sold 49,562 shares of Series B Preferred Stock under its ATM and received net proceeds of approximately $1.2 million. The Company also has the right to sell up to $50 million of its common stock using a second ATM facility. The underwriters of the common stock ATM also receive 3% of the gross proceeds. During the first quarter of 2022, no shares of common stock were issued under this ATM.

During the three months ended March 31, 2021, 858,000 common stock warrants were exercised at $7.50 each resulting in gross proceeds of $6,435,000.

|  |
| --- |
| 17 |

**11. REVENUE**

*Introduction*

The Company accounts for revenue in accordance with ASC 606, *Revenue from Contracts with Customers*. All revenue is recognized as our performance obligations are satisfied. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer, and is the unit of account under ASC 606. For revenue cycle management services, the Company recognizes revenue when services begin on medical billing claims, which is generally upon receipt of the claim from the provider. The Company estimates the value of the consideration it will earn over the remaining contractual period as services are provided and recognizes the fees over the term; this estimation involves predicting the amounts our clients will ultimately collect associated with the services they provided. Certain significant estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure revenue cycle management revenue under the standard.

Most of our current contracts with customers contain a single performance obligation. For contracts where we provide multiple services, such as where we perform multiple ancillary services, each service represents its own performance obligation. The standalone selling prices are based on the contractual price for the service.

We apply the portfolio approach as permitted by ASC 606 as a practical expedient to contracts with similar characteristics and we use estimates and assumptions when accounting for those portfolios. Our contracts generally include standard commercial payment terms. We have no significant obligations for refunds, warranties or similar obligations and our revenue does not include taxes collected from our customers.

*Disaggregation of Revenue from Contracts with Customers*

We derive revenue from five primary sources: (1) technology-enabled business solutions, (2) professional services, (3) printing and mailing services, (4) group purchasing services and (5) medical practice management services.

The following table represents a disaggregation of revenue for the three months ended March 31:

 SCHEDULE OF DISAGGREGATION OF REVENUE

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| **Healthcare IT:** |  |  |  |  |  |  |  |  |
| Technology-enabled business solutions |  | $ | 23,242 |  |  | $ | 25,845 |  |
| Professional services |  |  | 8,314 |  |  |  | 617 |  |
| Printing and mailing services |  |  | 463 |  |  |  | 383 |  |
| Group purchasing services |  |  | 134 |  |  |  | 188 |  |
| **Medical Practice Management:** |  |  |  |  |  |  |  |  |
| Medical practice management services |  |  | 3,188 |  |  |  | 2,735 |  |
| Total |  | $ | 35,341 |  |  | $ | 29,768 |  |
| Revenues |  | $ | 35,341 |  |  | $ | 29,768 |  |

*Technology-enabled business solutions:*

Revenue derived on an on-going basis from our technology-enabled solutions is typically billed as a percentage of payments collected by our customers.

Revenue cycle management services are the recurring process of submitting and following up on claims with health insurance companies in order for the healthcare providers to receive payment for the services they rendered. The Company typically invoices customers on a monthly basis based on the actual collections received by its customers and the agreed-upon rate in the sales contract. The fee for these services typically includes use of practice management software and related tools (on a SaaS basis), electronic health records (on a SaaS basis), medical billing services and use of mobile health solutions. We consider the services to be one performance obligation since the promises are not distinct in the context of the contract. The performance obligation consists of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers.

In many cases, our clients may terminate their agreements with 90 days’ notice without cause, thereby limiting the term in which we have enforceable rights and obligations, although this time period can vary between clients. Our payment terms are normally net 30 days. Although our contracts typically have stated terms of one or more years, under ASC 606 our contracts are considered month-to-month and accordingly, there is no financing component.

|  |
| --- |
| 18 |

For the majority of our revenue cycle management contracts, the total transaction price is variable because our obligation is to process an unknown quantity of claims, as and when requested by our customers over the contract period. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with variable consideration is subsequently resolved. Estimates to determine variable consideration, such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods, are updated at each reporting date. Revenue is recognized over the performance period using the input method.

Our proprietary, cloud-based practice management application automates the labor-intensive workflow of a medical office in a unified and streamlined SaaS platform. The Company has a large number of clients who utilize the Company’s practice management software, electronic health records software, patient experience management solutions, business intelligence software and/or robotic process automation software on a SaaS basis, but who do not utilize the Company’s revenue cycle management services. SaaS fees may be fixed based on the number of providers, or may be variable.

The medical billing clearinghouse service takes claim information from customers, checks the claims for errors and sends this information electronically to insurance companies. The Company invoices customers on a monthly basis based on the number of claims submitted and the agreed-upon rate in the agreement. This service is provided to medical practices and providers to medical practices who are not revenue cycle management customers. The performance obligation is satisfied once the relevant submissions are completed.

Additional services such as coding, credentialing and transcription are sometimes rendered in connection with the delivery of revenue cycle management and related medical services. The Company invoices customers monthly, based on the actual amount of services performed at the agreed-upon rate in the contract. These services are only offered to revenue cycle management customers. These services do not represent a material right because the services are optional to the customer and customers electing these services are charged the same price for those services as if they were on a standalone basis. Each individual coding, credentialing or transcription transaction processed represents a performance obligation, which is satisfied over time as that individual service is rendered.

*Professional services:*

Our professional services include an extensive set of services including EHR vendor-agnostic optimization and activation, project management, IT transformation consulting, process improvement, training, education and staffing for large healthcare organizations including health systems and hospitals. Revenue is recorded monthly on a time and materials or a fixed rate basis. This is a separate performance obligation from any RCM or SaaS services provided, for which the Company receives and records monthly fees. The performance obligation is satisfied over time as the professional services are rendered.

*Printing and mailing services:*

The Company provides printing and mailing services for both revenue cycle management customers and a non- revenue cycle management customer, and invoices on a monthly basis based on the number of prints, the agreed-upon rate per print and the postage incurred. The performance obligation is satisfied once the printing and mailing is completed.

|  |
| --- |
| 19 |

*Group purchasing services:*

The Company provides group purchasing services which enable medical providers to purchase various vaccines directly from selected pharmaceutical companies at a discounted price. Currently, there are approximately 4,000 medical providers who are members of the program. Revenue is recognized as the vaccine shipments are made to the medical providers. Fees from the pharmaceutical companies are paid either quarterly or annually and the Company adjusts its revenue accrual at the time of payment. The Company makes significant judgments regarding the variable consideration which we expect to be entitled to for the group purchasing services which includes the anticipated shipments to the members enrolled in the program, anticipated volumes of purchases made by the members, and the changes in the number of members. The amounts recorded are constrained by estimates of decreases in shipments and loss of members to avoid a significant revenue reversal in the subsequent period. The only performance obligation is to provide the pharmaceutical companies with the medical providers who want to become members in order to purchase vaccines. The performance obligation is satisfied once the medical provider agrees to purchase a specific quantity of vaccines and the medical provider’s information is forwarded to the vaccine suppliers. The Company records a contract asset for revenue earned and not paid as the ultimate payment is conditioned on achieving certain volume thresholds.

For all of the above revenue streams other than group purchasing services, revenue is recognized over time, which is typically one month or less, which closely matches the point in time that the customer simultaneously receives and consumes the benefits provided by the Company. For the group purchasing services, revenue is recognized at a point in time. Each service is substantially the same and has the same periodic pattern of transfer to the customer. Each of the services provided above is considered a separate performance obligation.

*Medical practice management services:*

The Company also provides medical practice management services under long-term management service agreements to three medical practices. We provide the medical practices with the nurses, administrative support, facilities, supplies, equipment, marketing, RCM, accounting, and other non-clinical services needed to efficiently operate their practices. Revenue is recognized as the services are provided to the medical practices. Revenue recorded in the consolidated statements of operations represents the reimbursement of costs paid by the Company for the practices and the management fee earned each month for managing the practice. The management fee is based on either a fixed fee or a percentage of the net operating income.

The Company assumes all financial risk for the performance of the managed medical practices. Revenue is impacted by the amount of the costs incurred by the practices and their operating income. The gross billing of the practices is impacted by billing rates, changes in current procedural terminology code reimbursement and collection trends which in turn impacts the management fee that the Company is entitled to. Billing rates are reviewed at least annually and adjusted based on current insurer reimbursement practices. The performance obligation is satisfied as the management services are provided.

Our contracts for medical practice management services have approximately an additional 20 years remaining and are only cancellable under very limited circumstances. The Company receives a management fee each month for managing the day-to-day business operations of each medical group as a fixed fee or a percentage payment of the net operating income which is included in revenue in the consolidated statements of operations.

Our medical practice management services obligations consist of a series of distinct services that are substantially the same and have the same periodic pattern of transfer to our customers. Revenue is recognized over time, however for reporting and convenience purposes, the management fee is computed at each month end.

*Information about contract balances:*

As of March 31, 2022, the estimated revenue expected to be recognized in the future related to the remaining revenue cycle management performance obligations outstanding was approximately $4.4 million. We expect to recognize substantially all of the revenue for the remaining performance obligations over the next three months. Approximately $228,000 of the contract asset represents revenue earned, but not yet paid, from the group purchasing services.

Amounts that we are entitled to collect under the applicable contract are recorded as accounts receivable. Invoicing is performed at the end of each month when the services have been provided. The contract asset includes our right to payment for services already transferred to a customer when the right to payment is conditional on something other than the passage of time. For example, contracts for revenue cycle management services where we recognize revenue over time but do not have a contractual right to payment until the customer receives payment of their claim from the insurance provider. The contract asset also includes the revenue accrued, not received, for the group purchasing services.

|  |
| --- |
| 20 |

Changes in the contract asset are recorded as adjustments to net revenue. The changes primarily result from providing services to revenue cycle management customers that result in additional consideration and are offset by our right to payment for services becoming unconditional and changes in the revenue accrued for the group purchasing services. The contract asset for our group purchasing services is reduced when we receive payments from vaccine manufacturers and is increased for revenue earned, not received. The opening and closing balances of the Company’s accounts receivable, contract asset and deferred revenue are as follows:

 SCHEDULE OF ACCOUNTS RECEIVABLE, CONTRACT ASSET AND DEFERRED REVENUE

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Accounts Receivable, Net** | |  |  | **Contract Asset** | |  |  | **Deferred Revenue (current)** | |  |  | **Deferred Revenue**  **(long term)** | |  |
|  |  | ($ in thousands) | | | | | | | | | | | | | |  |
| Balance as of January 1, 2022 |  | $ | 17,006 |  |  | $ | 4,725 |  |  | $ | 1,085 |  |  | $ | 341 |  |
| Increase (decrease), net |  |  | 1,487 |  |  |  | (80 | ) |  |  | 55 |  |  |  | 49 |  |
| Balance as of March 31, 2022 |  | $ | 18,493 |  |  | $ | 4,645 |  |  | $ | 1,140 |  |  | $ | 390 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Balance as of January 1, 2021 |  | $ | 12,089 |  |  | $ | 4,105 |  |  | $ | 1,173 |  |  | $ | 305 |  |
| Beginning balance |  | $ | 12,089 |  |  | $ | 4,105 |  |  | $ | 1,173 |  |  | $ | 305 |  |
| Increase (decrease), net |  |  | 330 |  |  |  | 270 |  |  |  | 52 |  |  |  | (20 | ) |
| Balance as of March 31, 2021 |  | $ | 12,419 |  |  | $ | 4,375 |  |  | $ | 1,225 |  |  | $ | 285 |  |
| Ending balance |  | $ | 12,419 |  |  | $ | 4,375 |  |  | $ | 1,225 |  |  | $ | 285 |  |

*Deferred commissions:*

Our sales incentive plans include commissions payable to employees and third parties at the time of initial contract execution that are capitalized as incremental costs to obtain a contract. The capitalized commissions are amortized over the period the related services are transferred. As we do not offer commissions on contract renewals, we have determined the amortization period to be the estimated client life, which is three years. Deferred commissions were approximately $846,000 and $1.0 million at March 31, 2022 and 2021, respectively, and are included in the other assets amounts in the consolidated balance sheets.

**12. STOCK-BASED COMPENSATION**

In April 2014, the Company adopted the Medical Transcription Billing, Corp. 2014 Equity Incentive Plan (the “2014 Plan”), reserving 1,351,000 shares of common stock for grants to employees, officers, directors and consultants. During 2017, the 2014 Plan was amended and restated whereby an additional 1,500,000 shares of common stock and 100,000 shares of Series A Preferred Stock were added to the plan for future issuance. The 2014 Plan was amended and restated on April 14, 2017 (the “Amended and Restated Equity Incentive Plan”). During 2018, an additional 200,000 of Series A Preferred Stock were added to the plan for future issuance. In May 2020, an additional 2,000,000 shares of common stock and an additional 300,000 shares of Series A Preferred Stock were added to the 2014 Plan for future issuance. Some of the Series A Preferred Stock shares were subsequently redesignated as Series B Preferred Stock and were removed from the 2014 Plan. As of March 31, 2022, 856,479 shares of common stock and 38,454 shares of Series A Preferred Stock are available for grant. Permissible awards include incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, RSUs, performance stock and cash-settled awards and other stock-based awards in the discretion of the Compensation Committee of the Board of Directors including unrestricted stock grants.

The equity-based RSUs contain a provision in which the units shall immediately vest and become converted into common shares at the rate of one share per RSU, immediately after a change in control, as defined in the award agreement.

|  |
| --- |
| 21 |

***Common and preferred stock RSUs***

In February 2022, the Compensation Committee approved executive bonuses to be paid in shares of Series B Preferred Stock, with the number of shares and the amount based on specified criteria being achieved during the year 2022. The addition of the Series B Preferred Stock to the Amended and Restated Equity Incentive Plan is subject to shareholder approval at the Annual Meeting. The actual amount of shares will be settled in early 2023 based on the achievement of the specified criteria. For the three months ended March 31, 2022, an expense of approximately $134,000 was recorded for these bonuses based on the value of the shares at the grant date and recognized over the service period. The portion of the stock compensation expense to be used for the payment of withholding and payroll taxes is included in accrued compensation in the consolidated balance sheets. The balance of the stock compensation expense has been recorded as additional paid-in capital.

The following table summarizes the RSU transactions related to the common and preferred stock under the Equity Incentive Plan for the three months ended March 31, 2022 and 2021:

 DISCLOSURE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Common Stock** | |  |  | **Series A Preferred Stock** | |  |  | **Series B Preferred Stock** | |  |
| Outstanding and unvested shares at January 1, 2022 |  |  | 418,039 |  |  |  | 34,000 |  |  |  | — |  |
| Granted |  |  | 360,398 |  |  |  | — |  |  |  | 34,000 |  |
| Vested |  |  | (208,817 | ) |  |  | (34,000 | ) |  |  | — |  |
| Forfeited |  |  | (25,494 | ) |  |  | — |  |  |  | — |  |
| Outstanding and unvested shares at March 31, 2022 |  |  | 544,126 |  |  |  | — |  |  |  | 34,000 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Outstanding and unvested shares at January 1, 2021 |  |  | 382,435 |  |  |  | 44,000 |  |  |  | — |  |
| Granted |  |  | 395,100 |  |  |  | 34,000 |  |  |  | — |  |
| Vested |  |  | (226,525 | ) |  |  | (44,000 | ) |  |  | — |  |
| Forfeited |  |  | (5,023 | ) |  |  | — |  |  |  | — |  |
| Outstanding and unvested shares at March 31, 2021 |  |  | 545,987 |  |  |  | 34,000 |  |  |  | — |  |

The liability for the cash-settled awards and the liability for withheld taxes in connection with the equity awards was approximately $417,000 and $1.0 million at March 31, 2022 and December 31, 2021, respectively, and is included in accrued compensation in the consolidated balance sheets. During the quarter ended March 31, 2022, approximately $13,000 was paid in connection with the cash-settled awards. No amounts were paid in connection with cash-settled awards during the quarter ended March 31, 2021.

***Stock-based compensation expense***

The Company recognizes compensation expense on a straight-line basis over the total requisite service period for the entire award. For stock awards classified as equity, the market price of our common stock or preferred stock on the date of grant is used in recording the fair value of the award and includes the related taxes. For stock awards classified as a liability, the earned amount is marked to market based on the end of period common stock price.

The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2022 and 2021:

 SCHEDULE OF EMPLOYEE SERVICE SHARE-BASED COMPENSATION, ALLOCATION OF RECOGNIZED PERIOD COSTS

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Stock-based compensation included in** |  | **Three Months Ended March 31,** | | | | | |  |
| **the consolidated statements of operations:** |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Direct operating costs |  | $ | 217 |  |  | $ | 305 |  |
| General and administrative |  |  | 380 |  |  |  | 624 |  |
| Research and development |  |  | 70 |  |  |  | 137 |  |
| Selling and marketing |  |  | 220 |  |  |  | 201 |  |
| Total stock-based compensation expense |  | $ | 887 |  |  | $ | 1,267 |  |

**13. INCOME TAXES**

The income tax expense for the three months ended March 31, 2022 was approximately $64,000 comprised of a current tax expense of $28,000 and a deferred tax expense of $36,000. The income tax benefit for the three months ended March 31, 2021 was approximately $1,000, comprised of a current tax expense of $35,000 and a deferred tax benefit of $36,000.

|  |
| --- |
| 22 |

The current income tax provision for the three months ended March 31, 2022 and 2021 primarily relates to state minimum taxes and foreign income taxes. The deferred tax provision (benefit) for the three ended March 31, 2022 and 2021 relates to the book and tax difference of amortization on indefinite-lived intangibles, primarily goodwill. To the extent allowable, the federal deferred tax provision has been offset by the indefinite life net operating loss.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (CARES) Act was signed into law. Several new corporate tax provisions were included in the CARES Act, including, but not limited to, the following: increasing the limitation threshold for determining deductible interest expense, class life changes to qualified improvements (in general - from 39 years to 15 years), and the ability to carry back net operating losses incurred from tax years 2018 through 2020 up to the five preceding tax years. The Company has evaluated the income tax provisions of the CARES Act and determined the impact to be either immaterial or not applicable. Under the CARES Act, the Company took advantage of the payroll tax deferral provision. As of both March 31, 2022 and December 31, 2021, the Company has deferred approximately $934,000 of payroll taxes. This amount needs to be repaid by December 31, 2022.

The Company has incurred cumulative losses, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against the Federal and state deferred tax assets as of March 31, 2022 and December 31, 2021.

**14. FAIR VALUE OF FINANCIAL INSTRUMENTS**

Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgement associated with the inputs used to measure their value in one of the following three categories:

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities. We held no Level 1 financial instruments at March 31, 2022 or December 31, 2021.

Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 financial instruments include notes payable which are carried at cost and approximate fair value since the interest rates being charged approximate market rates.

Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instrument includes the fair value of contingent consideration related to completed acquisitions. The fair value at March 31, 2022 is based on discounted cash flow analysis reflecting the likelihood of achieving specified performance measures or events and captures the contractual nature of the contingencies, the passage of time and the associated discount rate. As of March 31, 2022, the contingent consideration is valued using a Monte Carlo simulation model.

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):

 SCHEDULE OF FAIR VALUE, LIABILITIES MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Fair Value Measurement at  Reporting Date Using Significant Unobservable Inputs, Level 3** | | | | | |  |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Balance - January 1, |  | $ | 3,090 |  |  | $ | — |  |
| Acquisitions |  |  | — |  |  |  | — |  |
| Change in fair value |  |  | (600 | ) |  |  | — |  |
| Payments |  |  | — |  |  |  | — |  |
| Balance - March 31, |  | $ | 2,490 |  |  | $ | — |  |

|  |
| --- |
| 23 |

**15. SEGMENT REPORTING**

The Company’s Chief Executive Officer and Executive Chairman jointly serve as the Chief Operating Decision Maker (“CODM”), organize the Company, manage resource allocations and measure performance among two operating and reportable segments: (i) Healthcare IT and (ii) Medical Practice Management.

The Healthcare IT segment includes revenue cycle management, SaaS solutions and other services. The Medical Practice Management segment includes the management of three medical practices. Each segment is considered a reporting unit. The CODM evaluates financial performance of the business units on the basis of revenue and direct operating costs excluding unallocated amounts that are mainly corporate overhead costs. Our CODM does not evaluate operating segments using asset or liability information. The accounting policies of the segments are the same as those disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 14, 2022. The following table presents revenues, operating expenses and operating income (loss) by reportable segment:

 SCHEDULE OF REVENUES, OPERATING EXPENSES AND OPERATING INCOME (LOSS) BY REPORTABLE SEGMENT

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31, 2022** | | | | | | | | | | | | | |  |
|  |  | ($ in thousands) | | | | | | | | | | | | | |  |
|  |  | **Healthcare IT** | |  |  | **Medical**  **Practice Management** | |  |  | **Unallocated Corporate**  **Expenses** | |  |  | **Total** | |  |
| Net revenue |  | $ | 32,153 |  |  | $ | 3,188 |  |  | $ | — |  |  | $ | 35,341 |  |
| Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Direct operating costs |  |  | 20,011 |  |  |  | 2,662 |  |  |  | — |  |  |  | 22,673 |  |
| Selling and marketing |  |  | 2,376 |  |  |  | 8 |  |  |  | — |  |  |  | 2,384 |  |
| General and administrative |  |  | 3,400 |  |  |  | 437 |  |  |  | 1,748 |  |  |  | 5,585 |  |
| Research and development |  |  | 985 |  |  |  | — |  |  |  | — |  |  |  | 985 |  |
| Change in contingent consideration |  |  | (600 | ) |  |  | — |  |  |  | — |  |  |  | (600 | ) |
| Depreciation and amortization |  |  | 2,852 |  |  |  | 88 |  |  |  | — |  |  |  | 2,940 |  |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 158 |  |  |  | — |  |  |  | — |  |  |  | 158 |  |
| Total operating expenses |  |  | 29,182 |  |  |  | 3,195 |  |  |  | 1,748 |  |  |  | 34,125 |  |
| Operating income (loss) |  | $ | 2,971 |  |  | $ | (7 | ) |  | $ | (1,748 | ) |  | $ | 1,216 |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31, 2021** | | | | | | | | | | | | | |  |
|  |  | ($ in thousands) | | | | | | | | | | | | | |  |
|  |  | **Healthcare IT** | |  |  | **Medical**  **Practice Management** | |  |  | **Unallocated Corporate**  **Expenses** | |  |  | **Total** | |  |
| Net revenue |  | $ | 27,033 |  |  | $ | 2,735 |  |  | $ | — |  |  | $ | 29,768 |  |
| Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Direct operating costs |  |  | 15,987 |  |  |  | 2,073 |  |  |  | — |  |  |  | 18,060 |  |
| Selling and marketing |  |  | 1,882 |  |  |  | 8 |  |  |  | — |  |  |  | 1,890 |  |
| General and administrative |  |  | 3,426 |  |  |  | 520 |  |  |  | 1,678 |  |  |  | 5,624 |  |
| Research and development |  |  | 2,026 |  |  |  | — |  |  |  | — |  |  |  | 2,026 |  |
| Depreciation and amortization |  |  | 2,749 |  |  |  | 82 |  |  |  | — |  |  |  | 2,831 |  |
| Impairment charges and unoccupied lease charges |  |  | 1,018 |  |  |  | — |  |  |  | — |  |  |  | 1,018 |  |
| Total operating expenses |  |  | 27,088 |  |  |  | 2,683 |  |  |  | 1,678 |  |  |  | 31,449 |  |
| Operating (loss) income |  | $ | (55 | ) |  | $ | 52 |  |  | $ | (1,678 | ) |  | $ | (1,681 | ) |

**16. SUBSEQUENT EVENT**

Effective April 1, 2022, the Company created a new subsidiary in Azad Jammu and Kashmir called MTBC Bagh (Private) Limited. This entity is 99.8% owned by CareCloud, Inc. and will include all of the revenues, costs, assets and liabilities for the local operations.

|  |
| --- |
| 24 |

***Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations***

The following is a discussion of our consolidated financial condition and results of operations for the three months ended March 31, 2022 and 2021, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “*Forward-Looking Statements*” on page 2 of this Quarterly Report on Form 10-Q.

**COVID-19 Pandemic**

While the COVID-19 pandemic did not materially adversely affect the Company’s consolidated financial results and operations during the three months ended March 31, 2022, economic and health conditions in the United States and across most of the globe continue to change. The Company expanded its telehealth operations, which is an alternative to office visits. However, not all physicians are using telehealth and not to the same extent as previous office visits.

The COVID-19 pandemic affected the Company’s operations in 2021 and may continue to do so indefinitely in the future. The pandemic may have an impact on the Company’s business, operations, and financial results and conditions, directly and indirectly, including, without limitation, impacts on the health of the Company’s management and employees, its operations, marketing and sales activities, and on the overall economy. The spread of the virus did not adversely affect the health and availability of our employees and staff. The scope and nature of these impacts, most of which are beyond the Company’s control, continue to evolve and the outcomes are uncertain.

Due to the above circumstances and as described generally in this Quarterly Report on Form 10-Q, the Company’s consolidated results of operations for the three months ended March 31, 2022 may not necessarily be indicative of the results to be expected for the full fiscal year. The Company is not aware of any certain event or circumstance that would require an update to its estimates or judgements or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates could change in the future as new information about future developments is obtained. Management cannot predict the future impact of the COVID-19 pandemic on the Company’s consolidated operations nor on economic conditions generally, including the effects on patient visits. The ultimate extent of the effects of the COVID-19 pandemic on the Company is uncertain and will depend on highly unpredictable factors such as the ultimate geographic spread of the disease, the severity of the disease, the duration of outbreak, and the effectiveness of any further developments globally and nationally. The Company will actively monitor the situation and take further action that is in the best interest of our employees, customers, partners, and stockholders.

**Overview**

The Company is a healthcare information technology company that provides Software-as-a-Service offerings (“SaaS”) and technology-enabled business solutions, which are often bundled, but are occasionally provided individually, together with related business services to healthcare providers and hospitals throughout the United States. Our integrated SaaS platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health record (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems.

At a high level, these solutions can be categorized as follows:

|  |  |  |
| --- | --- | --- |
|  | ● | Technology-enabled business solutions, which are often bundled but are occasionally provided individually, including: |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | ○ | EHRs, which are easy to use, integrated with our business services or offered as Software-as-a-Service (“SaaS”) solutions, and allow our healthcare provider clients to deliver better patient care, document their clinical visits effectively and thus potentially qualify for government incentives, reduce documentation errors and reduce paperwork; |
|  |  | ○ | PM software and related tools, which support our clients’ day-to-day business operations and workflows; |

|  |
| --- |
| 25 |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | ○ | Mobile Health (“mHealth”) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services; |
|  |  | ○ | Telehealth solutions, which allow healthcare providers to conduct remote patient visits; |
|  |  | ○ | Healthcare claims clearinghouse, which enables our clients to electronically scrub and submit claims to, and process payments from, insurance companies; |
|  |  | ○ | Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients; |
|  |  | ○ | RCM services, which include end-to-end medical billing, eligibility, analytics, and related services, all of which can often be provided either with our technology platform or through a third-party system; and |
|  |  | ○ | Professional services consisting of application and advisory services, revenue cycle services, data analytic services and educational training services. |

|  |  |  |
| --- | --- | --- |
|  | ● | Medical practice management services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services, nurses and administrative support staff. We also provide management, bill-paying and financial advisory services. |

Our solutions enable clients to increase financial and operational performance, streamline clinical workflows, get better insight through data, and make better business and clinical decisions, resulting in improvement in patient care and collections while reducing administrative burdens and operating costs.

The modernization of the healthcare industry is transforming nearly every aspect of a healthcare organization from policy to providers, clinical care to member services, devices to data, and ultimately the quality of the patient’s experience as a healthcare consumer. We create elegant, user-friendly applications that solve many of the challenges facing healthcare organizations. We partner with organizations to develop customized, best-in-class solutions to solve their specific challenges while ensuring they also meet future regulatory and organizational requirements and market demands.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of approximately 700 experienced health industry experts throughout the United States. These experts are supported by our highly educated and specialized offshore workforce of approximately 3,400 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model also allowed us to become a leading consolidator in our industry sector, gaining us a reputation for acquiring and positively transforming distressed competitors into profitable operations of CareCloud.

Adoption of our technology-enabled business solutions typically requires little or no upfront expenditure by a client. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients, as the vast majority of our revenues are based on a percentage of our clients’ collections. The fees we charge for our complete, integrated, end-to-end solution are very competitive and among the lowest in the industry. We estimate that we currently provide services to approximately 40,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 2,600 independent medical practices and hospitals representing 80 specialties and subspecialties in 50 states. In addition, we serve approximately 200 clients that are not medical practices, but are primarily service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services, and are based, in part, upon estimates where the precise number of practices or providers is unknown.

We service clients ranging from small practices, consisting of one to ten providers, to large practices with over 2,300 providers operating in multiple states, to community hospitals.

On January 8, 2020, through a merger with a subsidiary, the Company acquired CareCloud Corporation, a Delaware corporation which was subsequently renamed CareCloud Health, Inc. (“CCH”), which has developed a highly acclaimed cloud-based platform including EHR, PM and patient experience capabilities. The Company paid $11.9 million in cash, assumed a working capital deficiency of approximately $5.1 million and issued 760,000 shares of the Company’s Series A Preferred Stock and two million warrants for the purchase of the Company’s common stock at prices of $7.50 for two years and $10.00 per share for three years.

|  |
| --- |
| 26 |

On June 16, 2020, the Company purchased all of the issued and outstanding capital stock of Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively, “Meridian,” and sometimes referred to as “Meridian Medical Management”), a former GE Healthcare IT company that delivers advanced healthcare information technology solutions and services. The Company paid $11.9 million in cash, issued 200,000 shares of the Company’s Series A Preferred Stock and warrants to purchase 2,250,000 of the Company’s common stock with an exercise price per share of $7.50 for two years and assumed Meridian’s negative working capital and certain long-term lease liabilities where the space is either not being utilized or will be vacated shortly, with an aggregate value of approximately $4.8 million.

On June 1, 2021, CareCloud Acquisition Corp (“CAC”), a wholly-owned subsidiary, entered into an Asset and Stock Purchase Agreement (the “Purchase Agreement”) with MedMatica Consulting Associates, Inc., (“MedMatica”) whereby CAC purchased the assets of MedMatica and the stock of its wholly-owned subsidiary Santa Rosa Staffing, Inc. (“SRS”). MedMatica and SRS provide a broad range of specialty consulting services to hospitals and large healthcare groups, including certain consulting services related to healthcare IT applications services and implementations, practice management, and revenue cycle management. The total consideration paid at closing was $10 million in cash, net of $1.5 million of escrow withheld. A working capital adjustment of approximately $3.8 million was also paid at closing. The Purchase Agreement provides that if during the 18-month period commencing on June 1, 2021 (“the “Earn-Out Period”), CAC’s EBITDA and revenue targets are achieved, then CAC shall pay an earn-out up to a maximum of $8 million (the “Base Earn-Out”). If during the Earn-Out Period, CAC’s additional and increased EBITDA and revenue targets are achieved, then CAC shall pay an additional earn-out, up to a maximum of $5 million (the “Additional Earn-Out”, collectively, with the Base Earn-Out, the “Earn-Out”). CAC will have the right to offset the Earn-Out against any claim for which CAC is entitled to indemnification under the Purchase Agreement and against damages for breaches by the seller of the non-competition and non-solicitation provisions in the Purchase Agreement.

Our offshore operations in the Pakistan Offices and Sri Lanka accounted for approximately 11% and 12% of total expenses for the three months ended March 31, 2022 and 2021, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 81% for the three months ended March 31, 2022 and approximately 80% for the three months ended March 31, 2021). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions and leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., the Pakistan Offices and Sri Lanka.

**Key Performance Measures**

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

|  |
| --- |
| 27 |

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

|  |  |  |
| --- | --- | --- |
|  | ● | Income tax expense (benefit) or the cash requirements to pay our taxes; |
|  | ● | Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt; |
|  | ● | Foreign currency gains and losses and other non-operating expenditures; |
|  | ● | Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price; |
|  | ● | Depreciation and amortization charges; |
|  | ● | Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; |
|  | ● | Net loss on lease termination, impairment and unoccupied lease charges; and |
|  | ● | Change in contingent consideration. |

Set forth below is a presentation of our adjusted EBITDA for the three months ended March 31, 2022 and 2021:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Net revenue |  | $ | 35,341 |  |  | $ | 29,768 |  |
|  |  |  |  |  |  |  |  |  |
| GAAP net income (loss) |  |  | 1,140 |  |  |  | (1,964 | ) |
|  |  |  |  |  |  |  |  |  |
| Provision (benefit) for income taxes |  |  | 64 |  |  |  | (1 | ) |
| Net interest expense |  |  | 95 |  |  |  | 64 |  |
| Foreign exchange loss / other expense |  |  | (56 | ) |  |  | 244 |  |
| Stock-based compensation expense |  |  | 887 |  |  |  | 1,267 |  |
| Depreciation and amortization |  |  | 2,940 |  |  |  | 2,831 |  |
| Transaction and integration costs |  |  | 102 |  |  |  | 232 |  |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 158 |  |  |  | 1,018 |  |
| Change in contingent consideration |  |  | (600 | ) |  |  | - |  |
| Adjusted EBITDA |  | **$** | **4,730** |  |  | **$** | **3,691** |  |

Adjusted operating income and adjusted operating margin exclude the following elements that are included in GAAP operating income (loss):

|  |  |  |
| --- | --- | --- |
|  | ● | Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price; |
|  | ● | Amortization of purchased intangible assets; |
|  | ● | Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; |
|  | ● | Net loss on lease termination, impairment and unoccupied lease charges; and |
|  | ● | Change in contingent consideration. |

|  |
| --- |
| 28 |

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three months ended March 31, 2022 and 2021:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands) | | | | | |  |
| Net revenue |  | $ | 35,341 |  |  | $ | 29,768 |  |
|  |  |  |  |  |  |  |  |  |
| GAAP net income (loss) |  |  | 1,140 |  |  |  | (1,964 | ) |
| Provision (benefit) for income taxes |  |  | 64 |  |  |  | (1 | ) |
| Net interest expense |  |  | 95 |  |  |  | 64 |  |
| Other (income) expense - net |  |  | (83 | ) |  |  | 220 |  |
| GAAP operating income (loss) |  |  | 1,216 |  |  |  | (1,681 | ) |
| GAAP operating margin |  |  | 3.4 | % |  |  | (5.6 | %) |
|  |  |  |  |  |  |  |  |  |
| Stock-based compensation expense |  |  | 887 |  |  |  | 1,267 |  |
| Amortization of purchased intangible assets |  |  | 1,805 |  |  |  | 2,135 |  |
| Transaction and integration costs |  |  | 102 |  |  |  | 232 |  |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 158 |  |  |  | 1,018 |  |
| Change in contingent consideration |  |  | (600 | ) |  |  | - |  |
| Non-GAAP adjusted operating income |  | **$** | **3,568** |  |  | **$** | **2,971** |  |
| Non-GAAP adjusted operating margin |  |  | 10.1 | % |  |  | 10.0 | % |

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

|  |  |  |
| --- | --- | --- |
|  | ● | Foreign currency gains and losses and other non-operating expenditures; |
|  | ● | Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price; |
|  | ● | Amortization of purchased intangible assets; |
|  | ● | Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; |
|  | ● | Net loss on lease termination, impairment and unoccupied lease charges; |
|  | ● | Change in contingent consideration; and |
|  | ● | Income tax expense (benefit) resulting from the amortization of goodwill related to our acquisitions. |

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net loss to non-GAAP adjusted net income for the three months ended March 31, 2022 and 2021:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
|  |  | ($ in thousands except for per share amounts) | | | | | |  |
| GAAP net income (loss) |  | $ | 1,140 |  |  | $ | (1,964 | ) |
|  |  |  |  |  |  |  |  |  |
| Foreign exchange loss / other expense |  |  | (56 | ) |  |  | 244 |  |
| Stock-based compensation expense |  |  | 887 |  |  |  | 1,267 |  |
| Amortization of purchased intangible assets |  |  | 1,805 |  |  |  | 2,135 |  |
| Transaction and integration costs |  |  | 102 |  |  |  | 232 |  |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 158 |  |  |  | 1,018 |  |
| Change in contingent consideration |  |  | (600 | ) |  |  | - |  |
| Income tax expense (benefit) related to goodwill |  |  | 36 |  |  |  | (36 | ) |
| Non-GAAP adjusted net income |  | **$** | **3,472** |  |  | **$** | **2,896** |  |

|  |
| --- |
| 29 |

Set forth below is a reconciliation of our GAAP net loss attributable to common shareholders, per share to our non-GAAP adjusted net income per share:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
| GAAP net loss attributable to common shareholders, per share |  | $ | (0.19 | ) |  | $ | (0.36 | ) |
| Impact of preferred stock dividend |  |  | 0.27 |  |  |  | 0.22 |  |
| Net income (loss) per end-of-period share |  |  | 0.08 |  |  |  | (0.14 | ) |
|  |  |  |  |  |  |  |  |  |
| Foreign exchange loss / other expense |  |  | 0.00 |  |  |  | 0.02 |  |
| Stock-based compensation expense |  |  | 0.06 |  |  |  | 0.09 |  |
| Amortization of purchased intangible assets |  |  | 0.11 |  |  |  | 0.14 |  |
| Transaction and integration costs |  |  | 0.01 |  |  |  | 0.02 |  |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 0.01 |  |  |  | 0.07 |  |
| Change in contingent consideration |  |  | (0.04 | ) |  |  | 0.00 |  |
| Income tax expense (benefit) related to goodwill |  |  | 0.00 |  |  |  | 0.00 |  |
| Non-GAAP adjusted earnings per share |  | **$** | **0.23** |  |  | **$** | **0.20** |  |
|  |  |  |  |  |  |  |  |  |
| End-of-period common shares |  |  | 15,062,651 |  |  |  | 14,399,790 |  |
| In-the-money warrants and outstanding unvested RSUs |  |  | 790,926 |  |  |  | 2,698,127 |  |
| Total fully diluted shares |  |  | 15,853,577 |  |  |  | 17,097,917 |  |
| Non-GAAP adjusted diluted earnings per share |  | **$** | **0.22** |  |  | **$** | **0.17** |  |

For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding at the end of March 31, 2022 and 2021. Non-GAAP adjusted diluted earnings per share was computed using an as-converted method and includes warrants that are in-the-money as of that date as well as outstanding unvested RSUs. Non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share do not take into account dividends paid on Preferred Stock. No tax effect has been provided in computing non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

**Key Metrics**

In addition to the line items in our consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

*Providers and Practices Served:* As of March 31, 2022, we provided services to an estimated universe of approximately 40,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,600 independent medical practices and hospitals. In addition, we served approximately 200 clients who were not medical practices, but are service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

|  |
| --- |
| 30 |

**Sources of Revenue**

*Revenue:* We primarily derive our revenues from subscription-based technology-enabled business solutions, reported in our Healthcare IT segment, which are typically billed as a percentage of payments collected by our customers. This fee includes RCM, as well as the ability to use our EHR, practice management system and other software as part of the bundled fee. These solutions accounted for approximately 66% and 87% of our revenues during the three months ended March 31, 2022 and 2021, respectively. Other healthcare IT services, including printing and mailing operations, group purchasing and professional services, represented approximately 25% and 4% of revenues for the three months ended March 31, 2022 and 2021, respectively.

We earned approximately 9% and 9% of our revenue from medical practice management services during both the three months ended March 31, 2022 and 2021. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Medical Practice Management segment.

**Operating Expenses**

*Direct Operating Costs.* Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the consolidated statements of operations.

*Selling and Marketing Expense.* Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

*General and Administrative Expense.* General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees.

*Research and Development Expense.* Research and development expense consists primarily of personnel-related costs, software expense and third-party contractor costs.

*Contingent Consideration.* Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

*Depreciation and Amortization Expense.* Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our medical practice management clients is amortized on a straight-line basis over a period of twelve years.

*Net loss on lease termination, Impairment and Unoccupied Lease Charges.* Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as the result of early lease terminations. Impairment charges represent charges recorded for a leased facility no longer being used by the Company and a non-cancellable vendor contract where the services are no longer being used. Unoccupied lease charges represent the portion of lease and related costs for vacant space not being utilized by the Company.

*Interest and Other Income (Expense).* Interest expense consists primarily of interest costs related to our line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains (losses) and income earned from temporary cash investments.

*Income Tax.* In preparing our consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of March 31, 2022 and December 31, 2021.

**Critical Accounting Policies and Estimates**

The critical accounting policies and estimates used in the preparation of our consolidated financial statements that we believe affect our more significant judgments and estimates used in the preparation of our consolidated financial statements presented in this Report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.

|  |
| --- |
| 31 |

*Leases:*

We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability (current portion) and operating lease liability (noncurrent portion) in the consolidated balance sheets at March 31, 2022 and December 31, 2021. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

We use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease term includes options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the consolidated balance sheet. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the leased and non-leased components as a single lease component. Some leases include escalation clauses and termination options that are factored into the determination of the future lease payments when appropriate.

*Capitalized software costs*:

All of our software is considered internal use for accounting purposes, as we do not market or sell our software. As a result, we capitalize certain costs associated with the creation of internally-developed software for internal use. The total of these costs is recorded in Intangible assets – net in our consolidated balance sheets.

We capitalized costs incurred during the application development stage related to our internal use software. Costs incurred during the application development phase are capitalized only when we believe it is probable that the development will result in new or additional functionality. The types of costs capitalized during the application development phase consist of employee compensation, employee benefits and employee stock- based compensation. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Capitalized internal-use software is amortized on a straight-line basis over its estimated useful life when the asset has been placed in service for general availability.

Significant judgments related to internally-developed software include determining whether it is probable that projects will result in new or additional functionality; concluding on when the application development phase starts and ends; and deciding which costs, especially employee compensation costs, should be capitalized. Additionally, there is judgment applied to the useful lives of capitalized software; we have concluded that the useful lives for capitalized internally-developed software is three years.

Company management employs its best estimates and assumptions in determining the appropriateness of the judgments noted above on a project-by-project basis during initial capitalization as well as subsequent measurement. While we believe that our approach to estimates and judgments is reasonable, actual results could differ, and such differences could lead to an increase or decrease in expense.

As of March 31, 2022 and December 31, 2021, the carrying amounts of internally-developed capitalized software in use was $13.1 million and $11.6 million, respectively. The increase in the capitalized software costs represents the continued investment in proprietary technology.

There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022.

|  |
| --- |
| 32 |

**Results of Operations**

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |
| Net revenue |  |  | 100.0 | % |  |  | 100.0 | % |
| Operating expenses: |  |  |  |  |  |  |  |  |
| Direct operating costs |  |  | 64.2 | % |  |  | 60.7 | % |
| Selling and marketing |  |  | 6.7 | % |  |  | 6.3 | % |
| General and administrative |  |  | 15.8 | % |  |  | 18.9 | % |
| Research and development |  |  | 2.8 | % |  |  | 6.8 | % |
| Change in contingent consideration |  |  | (1.7 | %) |  |  | 0.0 | % |
| Depreciation and amortization |  |  | 8.3 | % |  |  | 9.5 | % |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 0.4 | % |  |  | 3.4 | % |
| Total operating expenses |  |  | 96.5 | % |  |  | 105.6 | % |
|  |  |  |  |  |  |  |  |  |
| Operating income (loss) |  |  | 3.5 | % |  |  | (5.6 | %) |
|  |  |  |  |  |  |  |  |  |
| Interest expense - net |  |  | 0.3 | % |  |  | 0.2 | % |
| Other income (expense) - net |  |  | 0.2 | % |  |  | (0.7 | %) |
| Income (loss) before income taxes |  |  | 3.4 | % |  |  | (6.5 | %) |
| Income tax provision (benefit) |  |  | 0.2 | % |  |  | (0.0 | %) |
| Net income (loss) |  |  | 3.2 | % |  |  | (6.5 | %) |

***Comparison of the three months ended March 31, 2022 and 2021***

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended  March 31,** | | | | | |  |  | **Change** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |  | **Amount** | |  |  | **Percent** | |  |
|  |  | ($ in thousands) | | | | | | | | | | | | | |  |
| Net revenue |  | $ | 35,341 |  |  | $ | 29,768 |  |  | $ | 5,573 |  |  |  | 19 | % |

*Net Revenue.* Net revenue of $35.3 million for the three months ended March 31, 2022 increased by $5.6 million or 19% from net revenue of $29.8 million for the three months ended March 31, 2021. Revenue for the three months ended March 31, 2022 includes approximately $7.3 million from customers acquired in the medSR acquisition. Revenue for the three months ended March 31, 2022 includes $23.2 million relating to technology-enabled business solutions, $8.3 million related to professional services and $3.2 million for medical practice management services.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |  | **Change** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |  | **Amount** | |  |  | **Percent** | |  |
|  |  | ($ in thousands) | | | | | | | | | | | | | |  |
| Direct operating costs |  | $ | 22,673 |  |  | $ | 18,060 |  |  | $ | 4,613 |  |  |  | 26 | % |
| Selling and marketing |  |  | 2,384 |  |  |  | 1,890 |  |  |  | 494 |  |  |  | 26 | % |
| General and administrative |  |  | 5,585 |  |  |  | 5,624 |  |  |  | (39 | ) |  |  | (1 | %) |
| Research and development |  |  | 985 |  |  |  | 2,026 |  |  |  | (1,041 | ) |  |  | (51 | %) |
| Change in contingent consideration |  |  | (600 | ) |  |  | - |  |  |  | (600 | ) |  |  | (100 | %) |
| Depreciation |  |  | 449 |  |  |  | 460 |  |  |  | (11 | ) |  |  | (2 | %) |
| Amortization |  |  | 2,491 |  |  |  | 2,371 |  |  |  | 120 |  |  |  | 5 | % |
| Net loss on lease termination, impairment and unoccupied lease charges |  |  | 158 |  |  |  | 1,018 |  |  |  | (860 | ) |  |  | (84 | %) |
| Total operating expenses |  | $ | 34,125 |  |  | $ | 31,449 |  |  | $ | 2,676 |  |  |  | 9 | % |

*Direct Operating Costs.* Direct operating costs of $22.7 million for the three months ended March 31, 2022 increased by $4.6 million or 26% compared to direct operating costs of $18.1 million for the three months ended March 31, 2021. During the three months ended March 31, 2022, salary costs increased by $1.9 million, and outsourcing and processing costs increased by $2.3 million. The increase in these costs for the three months ended March 31, 2022 were primarily related to the medSR acquisition.

|  |
| --- |
| 33 |

*Selling and Marketing Expense.* Selling and marketing expense of $2.4 million for the three months ended March 31, 2022 increased by $494,000 or 26% from selling and marketing expense of $1.9 million for the three months ended March 31, 2021. The increase was primarily related to additional emphasis on sales and marketing activities.

*General and Administrative Expense.* General and administrative expense of $5.6 million for the three months ended March 31, 2022 decreased by $39,000 or 1% compared to three months ended March 31, 2021. The three-month decrease in general and administrative expense was primarily related to an overall decrease in expenses offset by an increase in salaries and wages due to the medSR acquisition.

*Research and Development Expense.* Research and development expense of $985,000 for the three months ended March 31, 2022 decreased by approximately $1.0 million from research and development expense of $2.0 million for the three months ended March 31, 2021. The decrease represents less maintenance work on platforms generating revenue and more resources dedicated to development of new technology which is not yet in commercial use. During the three months ended March 31, 2022 and 2021, the Company capitalized approximately $2.3 million and $1.5 million of development costs in connection with its internal-use software, respectively.

*Change in Contingent Consideration.* The change of $600,000 for the three months ended March 31, 2022 reflects the estimated decrease in the fair value of the contingent consideration from the medSR acquisition.

*Depreciation.* Depreciation of $449,000 for the three months ended March 31, 2022 decreased by $11,000 or 2% from the depreciation of $460,000 for the three months ended March 31, 2021.

*Amortization Expense.* Amortization expense of $2.5 million for the three months ended March 31, 2022 increased by $120,000 or 5% from amortization expense of $2.4 million for the three months ended March 31, 2021. The increase was primarily related to the intangible assets acquired from the medSR acquisition as well as amortization of software which was previously capitalized and now placed into use.

*Net loss on lease termination, Impairment and Unoccupied Lease Charges.* Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as the result of early lease terminations. Impairment charges represent charges recorded for a leased facility no longer being used by the Company and a non-cancellable vendor contract where the services are no longer being used. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacant and not being utilized by the Company. The Company was able to turn back to the landlord one of the unused facilities effective January 1, 2022.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended  March 31,** | | | | | |  |  | **Change** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |  | **Amount** | |  |  | **Percent** | |  |
|  |  | ($ in thousands) | | | | | | | | | | | | | |  |
| Interest income |  | $ | 5 |  |  | $ | 15 |  |  | $ | (10 | ) |  |  | (67 | )% |
| Interest expense |  |  | (100 | ) |  |  | (79 | ) |  |  | (21 | ) |  |  | (27 | )% |
| Other income (expense) - net |  |  | 83 |  |  |  | (220 | ) |  |  | 303 |  |  |  | 138 | % |
| Income tax provision (benefit) |  |  | 64 |  |  |  | (1 | ) |  |  | (65 | ) |  |  | (6,500 | )% |

*Interest Income.* Interest income of $5,000 for the three months ended March 31, 2022 decreased by $10,000 from interest income of $15,000 for the three months ended March 31, 2021. The interest income represents interest earned on temporary cash investments.

*Interest Expense.* Interest expense of $100,000 for the three months ended March 31, 2022 increased by $21,000 or 27% from interest expense of $79,000 for the three months ended March 31, 2021. Interest expense includes the amortization of deferred financing costs, which was $30,000 and $36,000 during the three months ended March 31, 2022 and 2021, respectively.

|  |
| --- |
| 34 |

*Other Income (Expense) – net.* Other income – net was $83,000 for the three months ended March 31, 2022 compared to other expense – net of $220,000 for the three months ended March 31, 2021. Other income (expense) primarily represents foreign currency transaction gains and other expense primarily represents foreign currency transaction losses. These transaction gains and losses result from revaluing intercompany accounts whenever the exchange rate varies and are recorded in the consolidated statements of operations.

*Income Tax Provision (Benefit).* The provision for income taxes was $64,000 for the three months ended March 31, 2022 compared to the benefit for income taxes of $1,000 for the three months ended March 31, 2021. As a result of the Company having certain net operating losses with an indefinite life under the current Federal tax rules, the federal deferred tax liability was offset against the federal net operating loss to the extent allowable in 2022 and 2021. The current income tax expense for the three months ended March 31, 2022 was approximately $28,000 and includes state minimum taxes and foreign income taxes. The Company has incurred cumulative losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax losses difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at March 31, 2022 and December 31, 2021.

**Liquidity and Capital Resources**

During the three months ended March 31, 2022, there was positive cash flow from operations of $3.1 million and at March 31, 2022, the Company had $10.1 million in cash and restricted cash and positive working capital of $8.7 million. The Company has a revolving line of credit with SVB, and, as of March 31, 2022, there was a $6 million balance outstanding, which was repaid in early April. During the three months ended March 31, 2022, the Company sold 1,150,372 shares of Series B Preferred Stock and raised $26.6 million in net proceeds after fees and expenses.

The following table summarizes our cash flows for the periods presented:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended**  **March 31,** | | | | | |  |  | **Change** | | | | | |  |
|  |  | **2022** | |  |  | **2021** | |  |  | **Amount** | |  |  | **Percent** | |  |
|  |  | ($ in thousands) | | | | | | | | | |  |  |  | |  |
| Net cash provided by operating activities |  | $ | 3,087 |  |  | $ | 958 |  |  | $ | 2,129 |  |  |  | 222 | % |
| Net cash used in investing activities |  |  | (2,797 | ) |  |  | (2,219 | ) |  |  | (578 | ) |  |  | (26 | )% |
| Net cash (used in) provided by financing activities |  |  | (342 | ) |  |  | 1,157 |  |  |  | (1,499 | ) |  |  | (130 | )% |
| Effect of exchange rate changes on cash |  |  | (152 | ) |  |  | 174 |  |  |  | (326 | ) |  |  | (187 | % |
| Net (decrease) increase in cash and restricted cash |  | $ | (204 | ) |  | $ | 70 |  |  | $ | (274 | ) |  |  | (391 | )% |

Income before income taxes was $1.2 million for the three months ended March 31, 2022, which included $2.9 million of non-cash depreciation and amortization. The loss before income taxes for the three months ended March 31, 2021 was $2.0 million, which included $2.8 million of non-cash depreciation and amortization.

***Operating Activities***

Cash provided by operating activities was $3.1 million and $958,000 during the three months ended March 31, 2022 and 2021, respectively. The increase in net income of $3.1 million included the following changes in non-cash items: increase in depreciation and amortization of $135,000, decrease in stock-based compensation of $380,000, and an increase in the change in contingent consideration of $600,000. Revenue increased by $5.6 million for the three months ended March 31, 2022 compared to the three months ended March 31, 2021, and operating expenses increased by $2.7 million for the same period, primarily due to the acquisition of medSR.

Accounts receivable increased by $1.6 million for the three months ended March 31, 2022 compared with an increase of $522,000 for the three months ended March 31, 2021. Accounts payable, accrued compensation and accrued expenses decreased by $1.1 million during the three months ended March 31, 2022 compared with a decrease of $1.7 million for the three months ended March 31, 2021.

|  |
| --- |
| 35 |

***Investing Activities***

Net cash used in investing activities was $2.8 million and $2.2 million for the three months ended March 31, 2022 and 2021, respectively. Capital expenditures were $544,000 and $695,000 for the three months ended March 31, 2022 and 2021, respectively. The capital expenditures for the three months ended March 31, 2022 and 2021 primarily represented computer equipment purchased and leasehold improvements for the Pakistan Offices. Software development costs of $2.3 million and $1.5 million for the three months ended March 31, 2022 and 2021, respectively, were capitalized in connection with the development of software for providing technology-enabled business solutions.

***Financing Activities***

Net cash used by financing activities was $342,000 during the three months ended March 31, 2022 and cash provided by financing activities was $1.2 million during the three months ended March 31, 2021. The Company received net proceeds from the sale of Series B Preferred Stock of $26.6 million of which $20.0 million was used to redeem 800,000 shares of Series A Preferred Stock. Net repayments on the credit line were $2.0 million. Cash used in financing activities during the three months ended March 31, 2022 included $3.9 million of preferred stock dividends, $251,000 of repayments for debt obligations and $775,000 of tax withholding obligations paid in connection with stock awards issued to employees. Cash used in financing activities for the three months ended March 31, 2021 included $3.6 million of preferred stock dividends, $241,000 of repayment for debt obligations and $1.4 million of tax withholding obligations paid in connection with stock awards issued to employees.

**Contractual Obligations and Commitments**

We have contractual obligations under our line of credit. We were in compliance with all SVB covenants as of March 31, 2022. We also maintain operating leases for property and certain office equipment. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022.

**Off-Balance Sheet Arrangements**

As of March 31, 2022, and 2021, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the first quarter of 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of March 31, 2022, talkMD had not yet commenced operations.

***Item 3. Quantitative and Qualitative Disclosures about Market Risk***

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

***Item 4. Controls and Procedures***

*Evaluation of Disclosure Controls and Procedures*

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

|  |
| --- |
| 36 |

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of March 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective because of the material weakness in our internal control over financial reporting as disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. The material weakness was due to a lack of controls over the completeness and accuracy of key inputs related to the measurement of a non-routine transaction.

*Changes in Internal Control Over Financial Reporting*

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and l5d-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

*Remediation of a Material Weakness in Internal Control over Financial Reporting*

We recognize the importance of the control environment as it sets the overall tone for the Company and is the foundation for all other components of internal control. Consequently, we designed and implemented remediation measures to address the material weakness previously identified and enhanced our internal control over financial reporting. In light of the material weakness, we enhanced our processes and controls to verify the completeness and accuracy of key inputs related to non-routine transactions by requiring more detailed reviews by experienced staff and increased communication among our personnel and third party professionals with whom we consult regarding such transactions. The foregoing actions, which we believe remediated the material weakness in internal control over financial reporting, were completed as of March 31, 2022.

|  |
| --- |
| 37 |

**Part II. Other Information**

***Item 1. Legal Proceedings***

See discussion of legal proceedings in “Note 8, Commitments And Contingencies” of the Notes to Consolidated Financial Statements in this Quarterly Report, which is incorporated by reference herein.

***Item 1A. Risk Factors***

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I—Item 1A. “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on March 14, 2022, which could materially affect our business, financial condition and/or future results and may be further impacted by the coronavirus pandemic. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and/or future results.

***Item 2. Unregistered Sales of Equity Securities and Use of Proceeds***

***Issuer Redemption of Equity Securities***

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Period** |  | **Total number of shares of Series A Preferred Stock redeemed** | |  |  | **Average price paid per share of Series A Preferred Stock** | |  |  | **Total number of shares redeemed as part of publicly announced plans or programs** | |  |
| January 1-31, 2022 |  |  | - |  |  |  | - |  |  |  | - |  |
| February 1-28, 2022 |  |  | - |  |  |  | - |  |  |  | - |  |
| March 1-31, 2022 |  |  | 800,000 | (1) |  |  | $25.1375 | (1) |  |  | 800,000 | (1) |
| Total |  |  | 800,000 |  |  |  | $25.1375 |  |  |  | 800,000 |  |

(1) On February 15, 2022, we announced that we would redeem 800,000 shares of our Series A Preferred Stock. On March 18, 2022, we redeemed 800,000 shares of our Series A Preferred Stock for a cash redemption price of $25.00 per share, plus all accrued and unpaid dividends to, but not including, the redemption date of March 18, 2022 in an amount equal to $.1375 per share, for a total payment of $25.1375 per share.

***Item 3. Defaults upon Senior Securities***

Not applicable.

***Item 4. Mine Safety Disclosures***

Not applicable.

***Item 5. Other Information***

Not applicable.

|  |
| --- |
| 38 |

***Item 6. Exhibits***

|  |  |  |
| --- | --- | --- |
| **Exhibit Number** |  | **Exhibit Description** |
|  |  |  |
| 10.19 |  | [Sixth Loan Modification Agreement dated January 27, 2022, by and between the Company and SVB.](ex10-19.htm) |
| 31.1 |  | [Certification of the Company’s Principal Executive Officer pursuant to Rules 13a-14(a)/15d-14(a), of the Securities Exchange Act of 1934, as amended.](ex31-1.htm) |
| 31.2 |  | [Certification of the Company’s Principal Financial Officer pursuant to Rules 13a-14(a)/15d-14(a), of the Securities Exchange Act of 1934, as amended.](ex31-2.htm) |
| 32.1\* |  | [Certification of the Company’s Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm) |
| 32.2\* |  | [Certification of the Company’s Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-2.htm) |
| 101.INS |  | XBRL Instance |
| 101.SCH |  | XBRL Taxonomy Extension Schema |
| 101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase |
| 101.LAB |  | XBRL Taxonomy Extension Label Linkbase |
| 101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase |
| 101.DEF  104 |  | XBRL Taxonomy Extension Definition Linkbase  Cover Page Interactive Data File (embedded within the Inline XBRL document) |

\*The certifications on Exhibit 32 hereto are not deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.

|  |
| --- |
| 39 |

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  |  |
| --- | --- | --- |
|  | **CareCloud, Inc.** | |
|  |  |  |
|  | By: | */s/ A. Hadi Chaudhry* |
|  |  | A. Hadi Chaudhry |
|  |  | Chief Executive Officer |
|  |  | Date: May 9, 2022 |
|  |  |  |
|  | By: | */s/ Bill Korn* |
|  |  | Bill Korn |
|  |  | Chief Financial Officer |
|  |  | Date: May 9, 2022 |

|  |
| --- |
| 40 |